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   ABSTRACT	  
	  
Introduction:	  
The	  diagnosis	  of	  Arrhythmogenic	  Cardiomyopathy	  (AC)	  is	  challenging	  and	  often	  late	  after	  
disease	  onset.	  It	  relies	  on	  a	  scoring	  system	  of	  major	  and	  minor	  criteria,	  requiring	  several	  
clinical,	   instrumental	   and	   genetic	   tests.	   Diagnosis	   confirmation	   is	   often	   obtained	   by	  
invasive	   procedures	   like	   endomyocardial	   biopsy	   and	   electroanatomical	   mapping.	   At	  
present	  time,	  no	  circulating	  biomarkers	  are	  available	  for	  the	  diagnosis	  of	  AC.	  	  
We	   hypothesized	   that	   circulating	   microRNAs	   (miRNAs),	   which	   have	   been	   already	  
demonstrated	   as	   circulating	   biomarkers	   of	   many	   cardiac	   diseases	   (e.g.	   heart	   failure,	  
myocardial	  infarction,	  atrial	  fibrillation)	  may	  be	  used	  as	  potential	  diagnostic	  tools	  in	  AC.	  	  
Aims:	  	  
1. To	  screen	  the	  level	  of	  expression	  of	  miRNAs	  in	  plasma	  samples	  of	  AC	  and	  non-­‐AC	  
male	  subjects.	  
2. To	   assess	   the	   specificity	   of	   potential	   miRNAs	   in	   diagnosing	   AC.	   In	   particular	   to	  
identify	   the	   differential	   expression	   of	   plasma	  miRNAs	   in	   AC	   patients	   vs.	   healthy	  
controls	  (HC)	  and/or	  patients	  with	  ventricular	  arrhythmias	  of	  different	  aetiologies:	  
idiopathic	   ventricular	   arrhythmias	   (IVT)	   and	   patients	   with	   ischemic	   ventricular	  
arrhythmias	  (IC).	  	  
3. To	  evaluate	  a	  possible	  correlation	  between	  miRNAs	  expression	  and	  the	  severity	  of	  
the	  disease	  in	  terms	  of	  ventricular	  function	  and	  fibro-­‐adipose	  replacement	  of	  the	  
myocardium	   by	   means	   of	   ElectoAnatomic	   voltage	   Mapping	   [EAM]	   and	   Late	  
Gadolinium	   Enhancement	   (LGE)	   detected	   by	   Contrast	   Enhancement	   Cardiac	  
Magnetic	  Resonance	  (CE-­‐CMR)	  
4. To	   assess	   in	   cardiac	   stromal	   mesenchimal	   cells	   culture	   how	   different	   levels	   of	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Methods:	  	  
All	  patients	  with	  a	  history	  of	  ventricular	  arrhythmias	  referred	  to	  Arrhythmia	  Center	  of	  the	  
Cardiology	  Center	  Monzino	  (Milan),	  for	  transcatheter	  ablation	  were	  enrolled	  in	  the	  study	  
as	  well	  as	  a	  control	  cohort	  of	  patients	  matched	  in	  terms	  of	  age	  and	  sex.	  
All	  patients	  underwent:	  -­‐ CE-­‐CMR	  evaluating	  the	  volumes	  and	  function	  of	  the	  right	  and	  left	  ventricle	  (RV	  and	  
LV),	  the	  presence	  and	  extension	  of	  LGE;	  -­‐ Electroanatomic	  voltage	  mapping	  (CARTO)	  of	  RV	  and	  LV.	  	  -­‐ Endomyocardial	  biopsy,	  when	   indicated,	   to	  evaluate	   the	  presence	  and	  extension	  
of	  fibro-­‐fatty	  infiltration	  of	  the	  RV.	  	  -­‐ Blood	  sampling	  for	  molecular	  analysis	  of	  320	  miRNA	  expression.	  
Blood	   samples	   (5ml)	   were	   collected	   in	   EDTA	   coated	   tubes	   and	   the	   total	   RNA	   was	  
extracted	  from	  plasma.	  The	  expression	  of	  each	  single	  miRNA	  was	  evaluated	  using	  TaqMan	  
microRNA	   assays	   (Life	   Technologies)	   following	   manufacturer’s	   instructions.	   Validated	  
miRNAs	  expression	  data	  were	  analyzed	  using	  GraphPad	  Prism	  version	  5.03	  for	  Windows	  
and	   reported	   as	   mean	   ±	   standard	   deviation	   of	   the	   mean	   (SD).	   Cardiac	   Mesenchymal	  
Stromal	  Cells	  (C-­‐MSCs)	  from	  AC	  ventricular	  samples	  have	  been	  obtained	  in	  our	  laboratory	  
and	  have	  been	  used	  as	  in	  vitro	  model	  of	  AC	  and	  we	  decided	  to	  evaluate	  miR-­‐320a	  in	  this	  
model.	  In	  order	  to	  assess	  C-­‐MSCs	  involvement	  during	  adipogenesis	  we	  planned	  an	  in	  vitro	  
experiment	  to	  simulate	  AC	  development.	  We	  maintained	  the	  same	  plated	  number	  of	  C-­‐
MSCs	  in	  adipogenic	  medium	  for	  3	  days.	  	  
Results:	  
In	  the	  present	  study	  a	  total	  of	  114	  male	  subjects	  were	  enrolled:	  35	  patients	  were	  affected	  
by	  AC,	  35	  were	  HC,	  20	  were	  affected	  by	  IVT	  and	  24	  were	  affected	  by	  IC.	  
The	   level	   of	   expression	   of	   368	   miRNAs	   was	   screened	   in	   plasma	   of	   3	   symptomatic	   AC	  
patients	  and	  3	  age-­‐	  and	  sex-­‐matched	  healthy	  donors:	  150	  miRNAs	  were	  found	  expressed	  
in	  all	  screened	  plasma	  samples	  and	  14	  miRNAs	  resulted	  putatively	  regulated.	  	  
Among	  the	  top	  4	  regulated	  miRNAs,	  considering	  both	  relative	  fold	  change	  and	  statistical	  
significance,	   miR-­‐320a	   was	   confirmed	   to	   be	   regulated	   in	   an	   initial	   validation	   step,	  
performed	  by	  qRT-­‐PCR	  in	  the	  plasma	  of	  16	  HC	  and	  16	  AC	  patients,	  as	  defined	  by	  current	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guidelines.	   Therefore	   its	   expression	   was	   analyzed	   in	   all	   HC	   and	   AC	   patients.	  MiR-­‐320a	  
showed	   a	   statistically	   significant	   lower	   expression	   in	   AC	   patients	   compared	   to	   HC	  
(0.42±0.04,	  p=0.008)	  and	  with	  a	  cut-­‐off	  value	  of	  ΔCt	  <-­‐5.55	  presented	  a	  sensitivity	  of	  65%	  
specificity	  of	  80%	  to	  discriminate	  AC	  patients.	  
We	  did	  not	  find	  any	  statistical	  significance	  in	  the	  level	  of	  expression	  of	  miR-­‐320a	  between	  
HC	  and	  IVT	  (fold	  1.09±0.5	  p=ns)	  as	  well	  as	  between	  HC	  and	  IC	  (fold	  0.74±0.22	  p=ns).	  
In	   evaluating	   the	   expression	   of	   miR-­‐320a	   in	   terms	   of	   the	   severity	   of	   the	   disease	   in	  
patients	   with	   AC	   we	   did	   not	   find	   any	   statistically	   significant	   correlation	   with	   major	  
arrhythmic	  events	  as	  well	  as	  no	  correlation	  with	  RV	  function.	  A	  significant	  correlation	  was	  
found	  between	  impairment	  of	  the	  LV	  function	  and	  ΔCt	  expression	  (r2=0.20	  p<0.04).	  
Evaluating	  miR-­‐320a	  expression	   in	  12	  patients	  with	  AC	  we	   found	  a	   trend	  of	   statistically	  
significance	   with	   the	   extension	   of	   scar	   areas	   detected	   by	   unipolar	   electroanatomic	  
mapping	  and	  LGE	  (p=0.07).	  
The	  results	  from	  the	  in	  vitro	  study	  on	  C-­‐MSC,	  showed	  a	  lower	  expression	  of	  miR-­‐320a	  in	  
AC	  C-­‐MSCs	  compared	  to	  non-­‐AC	  C-­‐MSCs	  (0.44±0.08,	  p=ns).	  	  
Conclusions:	  
This	  is	  the	  first	  study	  that	  evaluates	  the	  diagnostic	  potential	  of	  circulating	  miRNAs	  in	  AC.	  
Plasma	  levels	  of	  mir-­‐320a	  are	  consistently	  lower	  in	  AC	  patients	  compared	  to	  HC,	  IVT	  and	  
IC	  subjects	  and	  has	  a	  fairly	  good	  accuracy	  in	  discriminating	  AC	  vs.	  IVT	  patients.	  Low	  miR-­‐
320a	   plasma	   concentrations	   may	   represent	   a	   new	   potential	   biomarker	   for	   AC.	   Plasma	  
concentration	  of	  miR-­‐320a	  seems	  to	  demonstrate	  an	  inverse	  correlation	  with	  AC	  severity.	  	  
MiR-­‐320a	   regulation	   in	  a	  cardiac	  cellular	  model	  of	  AC	  during	   induced	  adipogenesis	  may	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Introduzione:	  
La	   diagnosi	   di	   Cardiomiopatia	   Aritmogena	   (CA)	   risulta	   essere	   spesso	   una	   sfida	   per	   il	  
cardiologo	  clinico	  e	  viene	  talvolta	  effettuata	  in	  ritardo	  rispetto	  all'insorgenza	  dei	  sintomi.	  
Si	   basa	   sull’identificazione	   di	   criteri	   diagnostici	   ottenuti	   attraverso	   l’utilizzo	   di	   diverse	  
indagini	   clinico-­‐strumentali,	   talvolta	   invasive	   e	   tramite	   test	   genetici.	   Ad	   oggi	   nessun	  
marcatore	  bioumorale	  circolante	  è	  stato	  validato	  e	  utilizzato	  quale	  criterio	  diagnostico.	  	  
Abbiamo	  ipotizzato	  che	  i	  microRNA	  (miRNA)	  circolanti,	  già	  validati	  nella	  diagnosi	  di	  molte	  
altre	   malattie	   cardiache	   (insufficienza	   cardiaca,	   infarto	   miocardico,	   fibrillazione	   atriale)	  
possano	  essere	  utilizzati	  come	  potenziale	  strumento	  diagnostico	  nella	  CAVD.	  
Obiettivi:	  
1. Eseguire	  uno	  screening	  di	  miRNA	  in	  campioni	  di	  plasma	  di	  soggetti	  maschi	  sani	  o	  
affetti	  da	  CA.	  
2. Valutare	   la	   specificità	   e	   la	   sensibilità	   dei	  miRNA	   nel	   riconoscimento	   della	   CA.	   In	  
particolare	   identificare	   i	   diversi	   livelli	   d’espressione	   dei	   miRNA	   plasmatici	   nei	  
pazienti	  con	  CA	  rispetto	  ai	  controlli	  sani	  (CS)	  e/o	  ai	  pazienti	  con	  aritmie	  ventricolari	  
a	   diversa	   eziologia	   (tachicardia	   ventricolare	   idiopatica	   (TVI)	   o	   conseguente	   a	  
cardiopatia	  ischemica	  (CI).	  
3. Valutare	   la	   possibile	   correlazione	   tra	   l'espressione	   dei	   miRNA	   e	   la	   gravità	   della	  
malattia	   espressa	   in	   termini	   di	   numerosità	   degli	   eventi	   aritmici	   maggiori,	  
funzionalità	   ventricolare	   destra	   e	   sinistra	   e	   in	   termini	   di	   estensione	   della	  
sostituzione	   fibro-­‐adiposa	   ottenuta	   mediante	   mappaggio	   elettroanatomico	   e	  
risonanza	  magnetica	  cardiaca	  (RMC).	  	  
4. Valutare	   come	   la	   differente	   espressione	   dei	   miRNA	   circolanti	   identificati	   possa	  
regolare	  lo	  sviluppo	  e	  la	  progressione	  della	  sostituzione	  fibro-­‐adiposa	  in	  colture	  di	  
cellulle	  cardiache	  mesenchimali	  stromali	  (C-­‐MSC).	  
Metodi:	  
Sono	  stati	  arruolati	  nello	  studio	  tutti	  i	  pazienti	  con	  aritmie	  ventricolari,	  riferiti	  all’Unità	  di	  
Elettrofisiologia	   del	   Centro	   Cardiologico	   Monzino	   (Milano)	   per	   essere	   sottoposti	   ad	  
ablazione	  transcatetere	  e	  controlli	  sani.	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Tutti	  i	  pazienti	  sono	  stati	  sottoposti	  a:	  -­‐ RMC	  per	  valutazione	  dei	  volumi	  e	  funzionalità	  del	  ventricolo	  destro	  e	  sinistro	  e	  per	  
determinazione	  dell’estensione	  delle	  “scars”.	  	  -­‐ Mappaggio	  elettroanatomico	  intracavitario	  bipolare	  e	  unipolare	  (CARTO).	  -­‐ Biopsia	   endomiocardica,	   quando	   indicata	   per	   valutazione	   della	   presenza	   e	  
l’estensione	  della	  sostituzione	  fibro-­‐adiposa	  del	  ventricolo	  destro.	  -­‐ Prelievo	  di	  sangue	  venoso	  l'analisi	  molecolare	  di	  320	  miRNA.	  	  
I	   campioni	   di	   sangue	   (5	  ml)	   sono	   stati	   raccolti	   in	   provette	   EDTA	   e	   l'RNA	   totale	   è	   stato	  
estratto	  dal	  plasma.	  L'espressione	  di	  ogni	  singolo	  miRNA	  è	  stata	  valutata	  utilizzando	  saggi	  
TaqMan	   microRNA	   (Life	   Technologies)	   seguendo	   le	   istruzioni	   del	   produttore.	  	  
L’espressione	  dei	  MiRNA	  validati	  è	   stata	  analizzata	  utilizzando	  GraphPad	  Prism	  versione	  
5.03	   per	  Windows	   e	   riportati	   come	  media	   ±	   deviazione	   standard	   della	   media	   (SD).	   Le	  
cellule	   stromali	   mesenchimali	   cardiache	   (C-­‐MSC)	   sono	   state	   ottenute	   da	   un	   campione	  
bioptico	  di	  pazienti	  con	  sospetta	  CA.	  Al	  fine	  di	  valutare	  il	  coinvolgimento	  C-­‐MSC	  durante	  
adipogenesi	   è	   stato	   eseguito	   un	   esperimento	   in	   vitro	   per	   simulare	   lo	   sviluppo	   della	  
patologia.	  	  
Risultati:	  	  
114	  soggetti	  maschi	  sono	  stati	  arruolati	  nello	  studio:	  35	  soggetti	  affetti	  da	  CA,	  35	  soggetti	  
sani,	  20	  affetti	  da	  TVI	  e	  24	  da	  CI.	  
Il	  livello	  d’espressione	  di	  368	  miRNA	  circolanti	  è	  stato	  valutato	  su	  campioni	  di	  plasma	  di	  6	  
soggetti	  (3	  affetti	  da	  CA	  e	  soggetti	  sani).	  	  
Di	  150	  miRNA	  espressi	  in	  tutti	  i	  campioni	  di	  plasma,	  14	  miRNA	  sono	  risultati	  regolati.	  
Tra	  i	  4	  miRNA	  maggiormente	  regolati,	  il	  miR-­‐320a	  è	  stato	  validato	  inizialmente	  mediante	  
qRT-­‐PCR	  nel	  plasma	  di	  32	  soggetti	  (16	  controlli	  sani	  e	  16	  soggetti	  affetti	  da	  CA)	  
In	  seguito	  abbiamo	  valutato	  l’espressione	  di	  miR-­‐320a	  in	  tutti	  i	  soggetti	  dello	  studio.	  	  
I	   livelli	   d’espressione	   del	   miR-­‐320A	   sono	   risultati	   statisticamente	   inferiori	   nei	   soggetti	  
affetti	  da	  CA	  rispetto	  ai	  controlli	  sani	  (0,42	  ±	  0,04,	  p	  =	  0,008)	  con	  un	  valore	  di	  cut-­‐off	  (ΔCt	  
<-­‐5.55)	   il	  miR-­‐320a	  ha	  presentato	  una	  sensibilità	  del	  65%	  e	  una	  specificità	  dell’	  80%	  nel	  
discriminare	  I	  pazienti	  con	  CA.	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Non	  abbiamo	  trovato	  nessuna	  differenza	  statisticamente	  significativa	  nell’espressione	  di	  
miR-­‐320a	   tra	   soggetti	   sani	   e	   affetti	   da	   TVI	   (1,09	   ±	   0,5	   p	   =	   ns)	   come	   tra	   soggetti	   sani	   e	  
affetti	  da	  CI	  (0.74	  ±	  0.22	  p	  =	  ns).	  	  
Nei	   soggetti	   affetti	   da	   CA,	   non	   abbiamo	   trovato	   alcuna	   correlazione	   tra	   i	   livelli	  
d’espressione	   di	  miR-­‐320	   a	   e	   il	   verificarsi	   di	   eventi	   aritmici	  maggiori	   così	   come	   con	   gli	  
indici	   di	   funzionalità	   ventricolare.	   Una	   correlazione	   statisticamente	   significativa	   è	   stata	  
riscontrata	   tra	   i	   livelli	   di	   espressione	   del	   miR-­‐320a	   e	   la	   funzione	   ventricolare	   sinistra	  
(FE)(r2=0.20	  p<0.04).	  
In	  12	  dei	  pazienti	  con	  CA	  abbiamo	  trovato	  un	  trend	  di	  significatività	  statistica	  tra	  i	  livelli	  di	  
miR-­‐320	  a	   e	   le	   aree	  di	   “scar”	   al	  mappaggio	  elettroanatomico	  unipolari	   e	   la	   presenza	  di	  
LGE	  (p=0,07).	  
Dallo	  studio	  in	  vitro	  sulle	  C-­‐MSC	  abbiamo	  evidenziato	  una	  ridotta	  espressione	  di	  miR-­‐320	  
nelle	  cellule	  ottenute	  dai	  pazienti	  con	  CA	  rispetto	  alle	  cellule	  ottenute	  dagli	  altri	  soggetti	  
(0,44	  ±	  0,08,	  p=ns)	  	  
Conclusioni:	  	  
Questo	  è	  il	  primo	  studio	  in	  cui	  sia	  stata	  valutata	  l’utilità	  diagnostica	  dei	  miRNA	  circolanti	  
nella	  CA.	  I	  livelli	  plasmatici	  d’espressione	  del	  miR-­‐320a	  sono	  costantemente	  più	  bassi	  nei	  
soggetti	   affetti	   da	   CA	   rispetto	   a	   soggetti	   sani	   o	   con	   cardiopatia	   ischemica	   o	   affetti	   da	  
tachicardia	   ventricolare	   idiopatica	   e	   si	   è	   dimostrato	   in	   grado	   di	   discriminare	   con	   una	  
buona	  accuratezza	  i	  soggetti	  affetti	  da	  CA	  rispetto	  ai	  soggetti	  affetti	  da	  TVI.	  	  
I	  nostri	  dati	  preliminari	  suggeriscono	  miR-­‐320a	  quale	  potenziale	  marcatore	  bioumorale	  di	  
CA	  e	  sembrerebbero	  evidenziare	  una	  correlazione	  inversa	  tra	  i	  livelli	  d’espressione	  di	  miR-­‐
320a	  e	  la	  gravità	  della	  patologia.	  	  
La	   creazione	   di	   un	   modello	   cellulare	   di	   adipogenesi	   indotta	   in	   cellule	   mesenchimali	  
stromali	   cardiache	  mediante	   regolazione	  di	  miR-­‐320a	  potrebbe	  aprire	   la	   strada	   a	   futuri	  
studi	  meccanicistici	  sul	  controllo	  epigenetico	  dell’adipogenesi	  nella	  CA.	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INTRODUCTION	  
	  
1. Arrhythmogenic	  Cardiomyopathy	  
1.1 Definition	  
Arrhythmogenic	   Cardiomyopathy	   (AC)	   is	   a	   rare,	   genetic,	   inherited	   heart	   muscle	  
disease,	   that	   is	   a	   main	   cause	   of	   sudden	   cardiac	   death	   (SCD)	   due	   to	   ventricular	  
arrhythmias,	  especially	  in	  younger	  than	  35	  years	  and	  athletes1.	  	  
It	  was	  first	  described	  in	  1736	  by	  the	  Pope’s	  physician,	  Giovanni	  Maria	  Lancisi,	  in	  his	  book	  
entitled	  “De	  Motu	  Cordis	  et	  Aneurysmatibus”.	  He	  reported	  that	   there	  was	  a	   family	  who	  
had	   experienced	   pathologic	   right	   ventricle	   (RV),	   heart	   failure	   (HF)	   and	   SCD	   in	   four	  
generations.	  	  
The	  first	  comprehensive	  clinical	  description	  of	  the	  disease	  was	  reported	  by	  Marcus	  et	  al.	  
in	   1982,	   when	   he	   reported	   24	   adult	   cases	   with	   ventricular	   tachyarrhythmias	   with	   left	  
bundle	  branch	  morphology2.	  	  
AC	  has	  undergone	  several	  name	  changes.	  It	  was	  initially	  identified	  by	  Fontaine	  et	  al.	  as	  a	  
pre-­‐excitation	  syndrome,	  later	  was	  considered	  a	  dysplastic	  disorder	  and	  further	  expanded	  
to	  include	  the	  arrhythmic	  features	  to	  become	  Arrhythmogenic	  Right	  Ventricular	  Dysplasia	  
(ARVD)3.	   It	   is	   recently	   considered	   a	   cardiomyopathy	   and	   called	   “Arrhythmogenic	   Right	  
Ventricular	   Cardiomyopathy”	   (ARVC)4.	   Nowadays	   the	   encompassing	   term	  
“Arrhythmogenic	  Cardiomyopathy”	   (AC)	   is	   increasingly	  used	   in	  order	   to	  considerate	   the	  
whole	   spectrum	   of	   the	   disease	   than	   the	   only	   “right	   forms”,	   because	   there	   are	   many	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1.2 Pathology	  
The	   main	   aspect	   of	   the	   disease	   is	   the	   progressive	   replacement	   of	   the	   right	  
ventricular	  myocardium	  by	  fibrous	  and	  fibro-­‐adipose	  tissue,	  starting	  from	  the	  epicardium	  
and	  extending	   to	   the	  endocardium	  as	   to	  become	  transmural	   (Figure	  1).	   In	  addition,	   the	  
myocardium	  usually	  shows	  a	  marked	  atrophy	  at	  the	  free	  wall,	  accounting	  for	  thinned	  and	  
translucent	   appearance	   of	   the	  wall,	   even	   though	   the	   distance	   between	   the	   epicardium	  
and	  the	  endocardium	  may	  be	  preserved1.	  
The	   fibro-­‐adipose	   replacement	   interferes	  with	   electrical	   impulse	   conduction	   and	   is	   the	  
key	  cause	  of	  electrocardiographic	   typical	   features	  as	  epsilon	  waves,	   left	  or	   right	  bundle	  
branch	   block	   (LBBB,	   RBBB),	   late	   potentials,	   life-­‐threatening	   re-­‐entrant	   ventricular	  
arrhythmias	  and	  progression	  towards	  HF.	  
	  
Figure 1 | Illustration of adipose replacement of myocardium within the right ventricular 
wall6. 
Schematic illustration of adipose infiltration and substitution starting from the epicardium and extending to the 
endocardium as to become transmural. 
	  
AC	  may	  have	  a	  broader	  phenotypic	  spectrum	  with	  biventricular	  forms	  and	  in	  5%	  of	  
cases	  with	  predominant	  involvement	  of	  the	  left	  ventricle.	  The	  latter	  case,	  most	  frequently	  
in	   aged	   patients,	   is	   associated	   with	   marked	   cardiomegaly	   and	   increased	   risk	   of	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arrhythmias	   and	   heart	   failure	   (HF).	   In	   the	   early	   prodromal	   stage	   of	   the	   disease,	   called	  
“concealed	  phase”	  structural	  changes	  may	  be	  absent	  or	  subtle	  and	  confined	  to	  a	  localized	  
region	   of	   the	   RV,	   typically	   the	   inflow	   tract,	   outflow	   tract,	   or	   apex	   of	   the	   RV,	   at	   the	   so	  
called	  “triangle	  of	  dysplasia”7.	  Progression	  to	  more	  diffuse	  RV	  disease	  and	  left	  ventricular	  
(LV)	   involvement,	   typically	   affecting	   the	   posterior	   lateral	   wall,	   is	   common,	   but	   disease	  
expression	   is	   variable.	   Trans	   mural	   atrophy	   of	   the	   myocardium	   causes	   aneurysmal	  
dilatation	   and	   wall	   motion	   abnormalities	   and	   lead,	   in	   advanced	   stages,	   to	   HF.	   In	   the	  
“concealed	  phase”,	  individuals	  are	  often	  asymptomatic,	  but	  SCD	  may,	  occasionally,	  be	  the	  
first	  symptom8,	  9.	  
The	  histologic	  pattern,	   typical	  of	   the	  disease,	   is	  a	  progressive	  degeneration	  of	  myocytes	  
and	  consequent	  accumulation	  of	  fibro-­‐	  and	  fibro-­‐adipose	  tissue	  (Figure	  2).	  These	  changes	  
are	  often	  associated	  with	  the	  presence	  of	  inflammatory	  infiltrates	  (Figure	  2).	  It	  is	  not	  yet	  
clear	  whether	  the	  inflammation	  is	  caused	  by	  a	  reaction	  to	  apoptotic	  death	  of	  myocytes	  or	  
whether	  it	  results	  from	  viral	  infections	  or	  immune	  reactions.	  	  
The	  ultimate	  phenotype	  may	  resemble	  dilated	  cardiomyopathy.	  
	  
	  
Figure 2 | Autopsy heart in a young man who died suddenly playing basketball 10.	  
Top left demonstrates increased fat in the outer walls of the right ventricle and left ventricular posterolateral 
walls. A higher magnification of the right ventricle is seen at the top right image; the anterior wall is nearly 
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completely replaced with fat, and fibro-adipose irregular posterior wall involvement is seen. The bottom left 
image demonstrates a full thickness of the right ventricle stained with Masson trichrome. The residual muscle 
is present only in a band-like area of scarring, and subepicardial scarring is present as well. The characteristic 
myocyte vacuolization, depicted in the bottom right image, is seen in nearly all areas of ARVC within the 
scarred areas. 
	  
Most	  of	  the	  information	  on	  AC	  comes	  from	  studies	  of	  the	  usual	  form	  of	  the	  disease	  with	  
predominant	  RV	  involvement.	  However,	  recognition	  of	  a	  disease	  pattern	  characterized	  by	  
early	   and	   predominant	   LV	   involvement	   has	   increased.	   The	   left-­‐dominant	   AC	   (LDAC)	  
pattern	   should	   not	   be	   confused	   with	   the	   well-­‐known	   LV	   involvement	   observed	   in	   the	  
advanced	  stages	  of	  AC,	  as	  a	  result	  of	  disease	  progression.	  Clinical	  markers	  of	  LDAC	  include	  
ECG	   abnormalities	   that	   suggest	   left-­‐side	   involvement,	   such	   as	   lateral	   or	   inferolateral	   T-­‐
wave	   inversion	  (leads	  V5,	  V6,	  LI,	  and	  aVL)11,	  and	  ventricular	  arrhythmias	  of	  right	  bundle	  
branch	   block	   morphology	   that	   suggests	   an	   LV	   origin.	   True	   LDAC	   mirrors	   classic	   right-­‐
dominant	  AC,	  with	   the	   left	   ventricle	  more-­‐severely	  affected	   than	   the	   right	  ventricle	   (an	  
RV/LV	  volume	  ratio	  <1).	  	  
A	  far	  more-­‐sensitive	  indicator	  of	  left-­‐sided	  disease	  is	  late	  gadolinium	  enhancement,	  which	  
is	  frequently	  detected	  in	  a	  segment	  without	  a	  concomitant	  wall-­‐motion	  abnormality,	  and	  
thus	   precedes	   the	   onset	   of	   LV	   dysfunction	   or	   dilatation.	   Typically,	   LV	   late	   gadolinium	  
enhancement	   involves	   the	   inferolateral	   and	   inferoseptal	   regions,	   and	   affects	   the	  
subepicardial	  or	  midwall	  layers,	  similar	  to	  the	  histological	  pattern	  of	  fibrofatty	  myocardial	  
replacement	   observed	   at	   post-­‐mortem	   examination12.	   Septal	   late	   gadolinium	  
enhancement	   is	   present	   in	   >50%	   of	   cases	   of	   LDAC,	   unlike	   the	   right-­‐dominant	   classical	  
pattern	   in	   which	   septal	   involvement	   is	   unusual.	   Differential	   diagnosis	   of	   dilated	  
cardiomyopathy	   in	   patients	   with	   suspected	   AC	   is	   mandatory	   for	   risk-­‐stratification	   and	  
familial-­‐evaluation	   purposes.	   The	  main	   distinction	   in	   LDAC	   is	   a	   propensity	   to	   electrical	  
instability	   that	   exceeds	   the	   degree	   of	   ventricular	   dysfunction,	   compared	   with	   dilated	  
cardiomyopathy,	  where	   ventricular	   arrhythmias	   and	   sudden	   cardiac	   death	   occur	   in	   the	  
context	  of	  overt	  systolic	  dysfunction	  with	  symptoms	  of	  heart	  failure.	  Moreover,	  regional	  
involvement	   (by	   contrast	   with	   the	   global	   involvement	   in	   dilated	   cardiomyopathy)	   is	  
suggestive	   of	   AC,	   particularly	   when	   RV	   abnormalities	   are	   prominent.24	   Importantly,	  
patients	   with	   a	   moderate-­‐to-­‐severe	   decrease	   in	   LV	   function	   were	   excluded	   from	   a	  
diagnosis	  of	  AC	  by	  the	  1994	  Task	  Force	  criteria,	  but	  this	  restriction	  has	  been	  eliminated	  in	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the	  2010	  criteria.	  As	  recognized	  by	  the	  Task	  Force,	  awareness	   is	  growing	  that	  classic	  AC	  
with	  RV	  involvement	  is	  the	  most	  well-­‐recognized	  variant	  of	  a	  broad	  spectrum	  of	  disease	  
that	   includes	  LDAC	  and	  biventricular	   subtypes.	  The	   lack	  of	   specific	  diagnostic	  guidelines	  
contributes	  to	  the	  under-­‐recognition	  of	  these	  nonclassical	  variants	  of	  AC.	  Future	  revisions	  
of	   the	   Task	   Force	   criteria	  will	   need	   to	   address	   this	   disparity,	   by	   incorporating	   features	  
such	  as	  ventricular	  tachycardia	  of	  right	  bundle	  branch	  block	  morphology,	  subepicardial	  or	  
midmyocardial	   late	   gadolinium	   enhancement	   of	   the	   LV	   myocardium,	   and	   global	   or	  




AC	  is	  a	  rare	  primitive	  myocardial	  disease	  with	  an	  estimated	  prevalence	  of	  1:5,000	  
in	  the	  worldwide	  population14,	   15.	   Interestingly,	   it	   is	  more	  diffuse	  in	  the	  north	  of	  Italy;	   in	  
Veneto	   it	   reaches	   the	   peak	   of	   1:2,00016,	   17.	   Men	   are	   more	   frequently	   affected	   then	  
women	  in	  a	  ratio	  of	  3:118.	  AC	  is	  a	  devastating	  disease	  given	  that	  the	  first	  symptom	  is	  often	  
SCD.	   Data	   from	   literature	   indicate	   that	   11-­‐22%	   of	   cases	   of	   SCD	   in	   young	   athletes	   (<35	  
years)	  occurred	  during	  physical	  exercise	  are	  due	  to	  the	  undiagnosed	  presence	  of	  AC16.	  
1.4 Genetics	  
More	   than	   a	   decade	   elapsed	   between	   the	   recognition	   of	   familial	   AC,	   and	   the	  
identification	   of	   the	   first	   disease-­‐causing	   gene	   mutation.	   The	   difficulty	   in	   identifying	  
affected	   individuals	   in	   the	   families	   of	   patients	  with	   AC,	  mostly	   because	   of	   the	   variable	  
penetrance	   and	   the	   low	   sensitivity	   of	   diagnostic	   criteria	   in	   the	   familial	   forms	   of	   the	  
disease,	   represented	  a	  major	  obstacle	   to	  early	   linkage-­‐mapping	  studies	  and	  subsequent	  
candidate-­‐gene	  evaluation.	  	  
For	   the	   first	   time,	   in	  1994,	  a	  disease	   locus	  was	   identified	   in	   chromosome	  14	  by	   linkage	  
analysis	   in	   large	   families	   with	   dominant	   AC.	   Later	   in	   the	   year	   2000	  was	   an	   AC-­‐causing	  
gene	   mutation	   identified	   in	   JUP	   in	   a	   fully	   penetrant,	   autosomal-­‐recessive	   form	   of	   the	  
disease	   with	   an	   easily	   recognizable	   cardiocutaneous	   phenotype	   (Naxos	   disease).	   A	  
recessive	   mutation	   in	   DSP	   was	   subsequently	   found	   to	   cause	   another	   cardiocutaneous	  
syndrome,	   Carvajal	   disease,	  which	   is	   characterized	   at	   the	   cardiac	   level	   by	   biventricular	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involvement.	   Therefore,	   after	   many	   years	   of	   linkage-­‐analysis	   studies	   that	   led	   to	   the	  
identification	  of	  several	  disease	  loci,	  but	  no	  disease	  genes,	  the	  molecular	  basis	  of	  AC	  was	  
discovered	  by	  investigation	  of	  cardiocutaneous	  syndromes.	  In	  particular,	  a	  morphological	  
study	  of	  the	  heart	  of	  a	  patient	  with	  Carvajal	  disease,	  showed	  biventricular	  wall	   thinning	  
with	  aneurysms,	  myocardial	  atrophy,	  and	  fibrosis,	  which	  immediately	  suggested	  that	  the	  
disease-­‐causing	  gene	  mutations	  involved	  in	  that	  cardiocutaneous	  syndrome	  might	  also	  be	  
ideal	   candidates	   for	   the	   autosomal-­‐dominant	   form	   of	   AC.	   Consequently,	   in	   2002,	  
mutations	  in	  the	  DSP	  gene	  were	  identified	  in	  families	  that	  had	  been	  followed	  up	  since	  the	  
1980s	  in	  an	  outpatient	  clinic	  in	  Padua,	  Italy.	  
Subsequently,	   a	   variety	   of	   mutations	   have	   been	   found	   in	   other	   desmosomal	  
genes,	   including	  PKP2,	  DSG2,	   and	  DSC2.	  Mutations	   in	   JUP	   have	   been	   reported	   even	   in	  
dominant	  forms	  of	  AC,	  and	  in	  DSC2	  and	  PKP2	  in	  recessive	  variants	  of	  the	  disease.	  With	  the	  
exception	  of	  a	  few	  genes	  unrelated	  to	  the	  cell-­‐adhesion	  complex,	  such	  as	  RYR2	  (encoding	  
the	   ryanodine	   receptor	   2),	   TGFB3	   (transforming	   growth	   factor	   β3),	   and	   TMEM43	  
(transmembrane	  protein	   43,	   also	   known	   as	   protein	   LUMA),	   the	  most-­‐common	  disease-­‐
causing	  mutations	   occur	   in	   genes	   that	   encode	   desmosomal	   proteins.	  Mutations	   in	  DES	  
(desmin)	  and	  TTN	  (titin)	  have	  been	  proposed	  as	  novel	  causes	  of	  AC.	  	  
In	  about	  30-­‐50%	  of	  cases	  AC	  has	  a	  familiar	  occurrence,	  usually	  with	  an	  autosomal	  
dominant	  inheritance	  pattern,	  with	  low	  penetrance	  and	  variable	  expressivity19.	  	  
A	   rare	   autosomal	   recessive	   variant	   of	   the	   disease,	   called	   Naxos	   disease	   shows	   similar	  
myocardial	  involvement	  with	  typical	  palmoplantar	  keratosis	  and	  wooly	  hair20.	  
 Desmosomal	  mutations	  1.4.1
Approximately	   50%	   individuals,	   affected	   by	   the	   familial	   form	   of	   the	   disease,	  
harbour	  an	  autosomal	  dominant	  mutation	  in	  one	  of	  the	  five	  genes	  coding	  for	  components	  
of	   the	   cardiac	   desmosome:	   desmoplakin	   (DSP)21,	   plakoglobin	   (JUP)22,	   plakophilin	   2	  
(PKP2)23,	   24,	   desmoglein	   2	   (DSG2)25,	   and	   desmocollin	   2	   (DSC2)26	   (Figure	   3,	   Table	   1).	  
Recessive	  mutation	  of	  DSP	  and	   JUP	  has	  been	  reported	  associated	  with	  cardiocutaneous	  
disease,	  the	  Carvajal	  syndrome	  21	  and	  the	  Naxos	  disease,	  respectively27.	  
Desmosomes	   are	   complex	   cellular	   junctions	   located	   between	   adjacent	   cells	   with	  
structural	   and	   intracellular	   signalling	   function.	   Cell	   adhesion	   junctions	   preserve	   the	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proper	   function	  and	  structure	  of	  cardiac	  myocytes	  and	  epithelial	  cells	  of	   the	  skin	   in	   the	  
intercalated	  disks.	  The	  intercalated	  disk	  contains	  three	  different	  intercellular	  connections:	  
gap	   junctions,	   responsible	   for	   electric	   coupling	   between	   cells,	   adherens	   junctions,	   and	  
desmosomes	  both	  of	  which	  provide	  mechanical	  coupling	  by	  linking	  the	  cytoplasmic	  actin	  
and	  intermediate	  filaments,	  respectively.	  Furthermore,	  desmosomes	  play	  a	  crucial	  role	  in	  
organising	   and	  maintaining	   intercalated	   disks,	   thereby	   determining	   the	   preservation	   of	  
the	  electrical	  coupling	  between	  cells.	  	  
Diseases	   related	   to	   mutations	   in	   these	   proteins	   are	   manifested	   mainly	   in	   cardiac	   and	  
epitelial	   tissues,	   due	   to	   the	   continuous	   mechanical	   stress	   of	   the	   myocardium	   and	   the	  
epitelium	  that	  alters	  the	  cellular	  biomechanical	  behaviour.	  
	  
Figure 3 | Intercellular mechanical junction (desmosome) of the cardiomyocyte 28. 
(A) Transmission electron microscopy of cardiomyocyte desmosome. (B) Schematic representation of 
desmosome components. Core region mediates cell-cell adhesion and dense plaque provides attachment to 
the intermediate fi laments. There are three major groups of desmosomal proteins: transmembrane proteins 
(desmosomalcadherins) including desmocollins and desmogleins; desmoplakin, a plakin family protein that 
binds directly to intermediate fi laments (desmin in the heart); and linker proteins (armadillo family proteins) 
including plakoglobin and plakophilins which mediate interactions between the desmosomal cadherin tails and 
desmoplakin. IF=intermediate fi laments. PM=plasma membrane. 
	  
Indeed,	  the	  prevailing	  hypothesis	  on	  desmosomal	  gene	  mutations	  causing	  AC	  is	  based	  on	  
the	   effect	   of	   mechanical	   stress	   leading	   to	   the	   weakness	   of	   the	   intercellular	   junction	  
causing	   disruption	   and	   degeneration	   of	   myocytes	   followed	   by	   inflammation	   and	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reparative	  phenomena,	  which	  would	   lead	  to	  myocytes	  replacement,	  by	  fibro-­‐	  and	  fibro-­‐
adipose	   scar	   tissue	   (Figure	   4).	   In	   this	   structural	   model,	   environmental	   factors	   such	   as	  
exercise	   or	   inflammation	   could	   exacerbate	   impairment	   of	   cell	   adhesion	   and	   hasten	  
disease	  progression.	  	  
The	  right	  ventricle	  (RV)	  is	  considered	  more	  susceptible	  to	  damage	  than	  the	  left	  one	  both	  
due	  to	  its	  lower	  thickness	  of	  the	  walls	  and	  the	  physiological	  response	  dilated	  paid	  to	  the	  
exercise.	   Environmental	   factors	   such	   as	   exercise	   or	   inflammation	   caused	   by	   viral	  
infections	  may	  further	  weak	  desmosome	  structures	  accelerating	  AC	  progression.	  
Moreover,	  the	  fibro-­‐adipose	  substitution	  could	  be	  mediated	  by	  signalling	  interfering	  with	  
the	  Wnt/β-­‐catenin	  pathway	  29.	  
	  
Figure 4 | Cardiac-specific restriction of the desmosomal protein desmoplakin causes 
nuclear localization of plakoglobin and reduced Wnt/β-catenin signaling, recapitulating 
human ARVC 30.	  
AC predominantly affects the right ventricle of the heart. (B) The intercalated discs of cardiac myocytes are 
characterized by gap junctions, adherens junctions, and desmosomes. (C) Cell-cell adhesion is largely 
dependent on interaction of intracellular components of the desmosomal plaque such as desmoplakin and 
plakoglobin. (D) Plakoglobin delocalization and Wnt/β-catenin signaling reduction in mice cause increased 
expression of adipogenic and fibrogenic genes in vitro, abnormal cardiac adipose tissue and fibrosis in vivo, 
and ventricular arrhythmias similar to human AC. Interactions between signaling defects and mechanical 
stresses are likely to be involved in the genesis of the final phenotype. 
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 Non-­‐desmosomal	  mutations	  1.4.2
Mutations	   in	   genes	   encoding	   non-­‐desmosomal	   proteins	   are	   also	   implicate	   in	   AC.	  
Mutations	   in	   the	   5’	   or	   3’	   untranslated	   region	  of	   the	   transforming	   growth	   factor	   beta	   3	  
gene	   (TGFB3)	   have	   been	   described	   in	   AC	   patients.	   These	   mutations	   led	   to	   increased	  
expression	  of	  TGFB3,	  which	  has	  a	  pro-­‐fibrotic	  effect	  (Table	  1)	  31.	  	  
Missense	  mutations	   in	   the	  gene	  encoding	   the	   cardiac	   ryanodine	   receptor	   (RYR2)	   (Table	  
1),	  a	  calcium	  release	  channel	  in	  the	  sarcoplasmic	  reticulum,	  have	  been	  described	  in	  Italian	  
families	   with	   a	   distinct	   form	   of	   AC	   characterised	   by	   exercise-­‐induced	   ventricular	  
arrhythmias	   and	   a	   high	   penetrance	   32.	   RYR2	   mutations	   have	   also	   been	   identified	   in	  
families	   with	   catecholaminergic	   polymorphic	   ventricular	   tachycardia	   (CPVT)	   33,	   rising	  
suspicion	  of	  phenocopy.	  
Another	  founder	  mutation	  has	  been	  recognized	  in	  the	  gene	  encoding	  the	  transmembrane	  
protein	  43	  (TMEM43)	  (Table	  1)	  34,	  which	  cause	  a	  form	  of	  AC	  found	  to	  be	  fully	  penetrant	  
with	   prominent	   LV	   involvement.	   Notably,	   men	   carrying	   this	   mutation	   are	   prone	   to	  
exacerbate	  the	  disease	  at	  a	  younger	  age	  than	  women.	  It	  has	  been	  hypothesized	  that	  the	  
TMEM43	   mutation	   causes	   fibro-­‐adipose	   replacement	   of	   the	   myocardium	   inducing	   the	  
activation	  of	  the	  adipogenic	  transcription	  factor	  PPARγ.	  
In	   2010,	   Klauke	   et	   al.	   identified	   a	   case	   of	  missense	  mutation	   in	   the	   gene	   encoding	   for	  
desmin	   (DES)	   (Table	   1)	   35.	   Desmin	   is	   a	   cytoskeletal	   filament	   protein	   located	   in	   the	  
myocardium	  at	  the	  intercalated	  disk,	  and	  connected	  to	  the	  desmosomal	  plaque	  proteins	  
via	  desmoplakin,	   thus	  supporting	   the	  resistance	   to	  mechanical	   stress	  of	  cardiomyocytes	  
36.	  Mutations	  in	  DES	  gene	  are	  often	  involved	  in	  skeletal	  abnormalities.	  	  
Recently,	   Taylor	   and	   colleague	   identified	   in	   the	   gene	   coding	   for	   titin	   (TTN)	   (Table	   1)	   a	  
missense	  variant	  segregating	  in	  an	  AC	  family	  37.	  Titin,	  after	  myosin	  and	  actin,	  is	  the	  third	  
most	  abundant	  protein	  of	   striated	  muscle,	   and	  connects	   the	  Z-­‐line	   to	   the	  M-­‐line	   in	   the	  
sarcomere	  37-­‐39.	  	  
To	   date	   15	   mutations	   in	   the	   Phospholamban	   (PLN)	   (Table	   1)	   gene,	   a	   regulator	   of	   the	  
SERCA	  pump,	  has	  been	  described	  in	  association	  both	  with	  dilated	  cardiomyopathy	  (DCM)	  
and	  AC	  40.	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Finally	   in	   2012,	   four	   Lamin	   A/C	   (LMNA)	   (Table	   1)	   pathogenic	   variants	   were	   linked	   to	  
clinically	  severe	  forms	  of	  AC	  and	  to	  one	  case	  of	  sudden	  death.	  Therefore,	  this	  gene	  was	  




Gene Protein Inheritance Disease 
Desmosomal genes 
17q21 JUP Junction plakoglobin AR 
Naxos associated 
disease 
17q21 JUP Junction plakoglobin AD  
6p24 DSP Desmoplakin AR Carvajal syndrome 
6p24 DSP Desmoplakin AD LV involvement 
12p11 PKP2 Plakophilin 2 AD, AR  
18q12 DSG2 Desmoglein 2 AD LV involvement 





AD CPVT phenotype 
14q23–q24 TGFB3 
Transforming growth 






2q35 DES Desmin AD 
DCM and HC phenotype, 
early conduction disease 
2q31 TTN Titin AD 
Early conduction 
disease, AF 
1q11-q23 LMNA Lamin A/C AD DCM phenotype 
6q22.1 PLN Phospholamban AD DCM phenotype 
Table 1 | Schematic list of mutations involved in AC.  
AD=Autosomal Dominant; AR=Autosomal Recessive; LV=Left Ventricle AF=Atrial Fibrillation; 
CPVT=Catecholaminergic Polymorphic Ventricular Tachycardia; DCM=Dilated Cardiomyopathy 
HC=Hypertrophic Cardiomyopathy.	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1.5 Wnt	  pathway	  
Wnt	  signalling	  controls	  various	  cellular	  and	  biological	  processes,	  such	  as	  cellular	  adhesion	  
42,	  43,	  self-­‐renewal	  44,	  cancer	  development	  45,	  46,	  differentiation	  47,	  cell	  polarity,	  migration,	  
proliferation	  and	  development	  of	  various	  tissues	  48,	  49.	  	  
Wnts	   are	   secreted	   glycoproteins	   that	   signal	   through	   Frizzled	   (Fz)	   receptors	   50	   and	   low	  
density	   lipoprotein	   receptor-­‐related	   protein	   (LRP)	   co-­‐receptors	   51	   in	   order	   to	   play	  
autocrine	  and	  paracrine	  effects	  on	  cellular	  differentiation	  and	  growth.	  	  
When	  Wnt	  signalling	  is	  active	  glycogen	  synthase	  kinase	  3	  (GSK3)	  is	  inhibited.	  This	  loss	  of	  
GSK3	   activity	   allows	   cytosolic	   β-­‐catenin	   to	   accumulate	   and	   translocate	   to	   the	   nucleus	  
where	  it	  binds	  to	  the	  T-­‐cell	  factor	  (TCF)/lymphoid-­‐enhancing	  factor	  family	  of	  transcription	  
factors	  and	  activates	  transcription	  of	  Wnt-­‐regulated	  target	  genes	  52.	  On	  the	  other	  hand,	  
when	   Wnt	   signalling	   is	   suppressed	   GSK3	   phosphorylates	   β-­‐catenin	   and	   targets	   it	   for	  
ubiquitin-­‐mediated	   degradation	   53.	   Moreover,	   this	   pathway	   controls	   adipogenic	  
differentiation	  of	  pre-­‐adipocytes	  54,	   it	   is	  a	  key	  regulator	  during	  cardiac	  development	  and	  
injury	  55,	  and	   it	  represents	  regulatory	  mediators	  of	  the	  perturbed	  metabolic	  activities	  of	  
cancer	  cells.	  	  
Interestingly,	   plakoglobin	   (γ-­‐catenin)	   has	   approximately	   85%	   sequence	   identity	   to	   β-­‐
catenin.	   It	   has	   been	   suggested	   that	   their	   competition	   for	   DNA	   binding	   leads	   to	  
suppression	   of	   Wnt	   signalling	   and	   to	   transcriptional	   switch	   to	   adipogenesis	   29,	   56.	  
Furthermore,	   both	   nuclear	   localisation	   of	   plakoglobin	   and	   reduced	   canonical	   Wnt/β-­‐
catenin	  signalling	  have	  been	  proposed	  to	  contribute	  to	  AC	  adipogenesis	  29.	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Figure 5 | General overview of Wnt/β-catenin signaling (MacDonald, Tamai, et al.).  
In the absence of Wnt (Wnt off), CK1α/GSK3 phosphorylation of β-catenin ensures that cytoplasmic β-catenin 
is continually targeted for ubiquitin-mediated proteasomal degradation. This is mediated by the so-called ‘β-
catenin destruction complex’ which is held together by the key scaffolding protein, axin. When present (Wnt 
on), Wnt ligands bind to Frizzled and LRP6 receptors, resulting in a Dishevelled-dependent oligomerization of 
LRP6 and its CK1γ/GSK3-mediated phosphorylation. The resulting LRP6 signalosomes sequester Axin thus 
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1.6 Diagnosis	  
Suspicion	   of	   classical	   AC	   usually	   arises	  when	   adolescents	   or	   young	   adults	   present	  with	  
heart	   palpitations,	   syncope,	   or	   cardiac	   arrest.	   Ventricular	   tachycardia	   or	   premature	  
ventricular	  beats	  with	  left	  bundle	  branch	  morphology	  and	  T-­‐wave	  inversion	  in	  the	  V1	  to	  V3	  
leads	   on	   a	   12-­‐lead	   electrocardiogram	   (ECG)	   are	   common	   reasons	   to	   suspect	   AC.	   Less-­‐
common	   presentations	   are	   RV	   or	   biventricular	   heart	   failure,	   which	   can	   mimic	   dilated	  
cardiomyopathy.	  	  
The	   major	   challenge	   is	   to	   distinguish	   AC	   from	   a	   normal	   heart	   with	   physiological	  
adaptation	   to	   hemodynamic	   overload,	   such	   as	   occurs	   in	   athletes,	   and	   from	   so-­‐called	  
disease	  phenocopies,	  which	   include	  myocarditis,	  sarcoidosis,	   idiopathic	  RV	  outflow	  tract	  
tachycardia,	  and	  congenital	  heart	  disease	  with	  RV	  overload.	  
No	  single,	  gold-­‐standard	  criterion	  is	  sufficiently	  specific	  to	  establish	  reliably	  a	  diagnosis	  of	  
AC. Multiple	   parameters	   are	   needed,	   therefore,	   as	   included	   in	   the	   original	   1994	   Task	  
Force	   diagnostic	   criteria,	   which	   combined	   multiple	   sources	   of	   diagnostic	   information,	  
such	   as	   familial,	   electrocardiographic,	   arrhythmic,	   morphofunctional,	   and	  
histopathological	  findings.	  Although	  they	  provide	  an	  extremely	  useful	  common	  approach	  
to	  clinical	  diagnosis	  in	  index	  patients,	  the	  1994	  criteria	  have	  been	  shown	  to	  lack	  sensitivity	  
for	  the	   identification	  of	  early	  or	  minor	  phenotypes,	  particularly	   in	  the	  setting	  of	   familial	  
disease.A	  limitation	  of	  the	  original	  Task	  Force	  criteria	  was	  the	  lack	  of	  quantitative	  cut-­‐off	  
values	   for	   accurate	   grading	   of	   RV	   dilatation	   and	   dysfunction,	   and	   fibrofatty	  myocardial	  
replacement.	  
Diagnosis	   of	   AC	   is	   challenging	   because	   of	   the	   broad	   spectrum	  of	   phenotypic	   variations	  
and	  often	  could	  be	  performed	  later	  the	  onset	  of	  the	  disease.	  It	  relies	  on	  a	  scoring	  system	  
of	  “Major”	  and	  “Minor”	  criteria,	  proposed	  by	  Marcus	  et	  al.	   in	  1994,	  which	  consists	  of	  a	  
diagnostic	   algorithm	   based	   on	   structural,	   functional,	   and	   electrophysiological	   changes	  
typical	   of	   the	   disease	   (Table	   2)	   7,	   57.	   In	   particular,	   these	   clinical	   criteria	   comprise	   six	  
different	   categories	   including	   structural	   and	   histological	   findings,	   depolarisation	   and	  
repolarisation	   abnormalities,	   arrhythmias,	   and	   family	   history.	   “Major”	   and	   “Minor”	  
criteria	  were	  defined	  for	  each	  category.	  A	  diagnosis	  can	  be	  made	   if	  a	  patient	  fulfils	  two	  
major	  criteria,	  one	  major	  and	  two	  minor	  criteria,	  or	  four	  minor	  criteria,	  all	  from	  different	  
categories.	   It	   is	   considered	   borderline	   the	   diagnosis,	   which	   satisfy	   one	   major	   and	   one	  
	  	   23	  
minor,	  or	  three	  minor	  criteria.	  The	  proposed	  algorithm	  possesses	  sensitivity	  close	  to	  100%	  
and	   specificity	   of	   91%,	   but	   has	   the	   disadvantage	   of	   creating	   a	   group	   of	   patients	   with	  
uncertain	   diagnosis,	   which,	   according	   to	   present	   indications,	   must	   be	   periodically	   re-­‐
evaluated	  by	  imaging	  techniques.	  These	  1994	  criteria	  were	  found	  to	  be	  highly	  specific	  but	  
not	  sensitive	  enough.	  Indeed	  for	  many	  patients	  at	  risk	  a	  firm	  diagnosis	  cannot	  be	  reached.	  
To	  overcome	  this	  issue	  the	  criteria	  were	  modified	  in	  2010	  with	  the	  inclusion	  of	  the	  results	  
of	  genetic	  studies	  among	  the	  diagnostic	  criteria	  (Table	  2).	  	  
Anyway,	   diagnosis	   confirmation	   is	   often	   accomplished	   by	   invasive	   procedures	   such	   as	  
endomyocardial	  biopsy	  58,	  59.	  
	  
I.	  Global	  and/or	  regional	  dysfunction	  and	  structural	  alterations	  
Major	   Minor	  
• Severe	   dilatation	   and	   reduction	   of	   RV	   ejection	  
fraction	  with	  little	  or	  no	  LV	  impairment	  
• Localized	  RV	  aneurysms	  
• Severe	  segmental	  dilatation	  of	  the	  RV	  
• Mild	   global	   RV	   dilatation	   and/or	   reduced	   ejection	  
fraction	  with	  normal	  LV.	  
• Mild	  segmental	  dilatation	  of	  the	  RV	  
• Regional	  RV	  hypokinesis	  
	   	  
II.	  Tissue	  characterisation	  of	  the	  wall	  
Major	   Minor	  
Fibrofatty	  replacement	  of	  myocardium	  on	  endomyocardial	  biopsy	  
	   	  
III.	  Repolarisation	  abnormalities	  
Major	   Minor	  
• Inverted	  T	  waves	   in	  right	  precordial	   leads	   (V1,	  V2,	  
and	  V3)	  	  
• Epsilon	  waves	  in	  V1	  -­‐	  V3	  
• Localized	  prolongation	  (>110	  ms)	  of	  QRS	  in	  V1	  -­‐	  V3	  
• Inverted	  T	  waves	  in	  V2	  and	  V3	  in	  an	  individual	  over	  
12	   years	   old,	   in	   the	   absence	   of	   a	   right	   bundle	  




Major	   Minor	  
Nonsustained	   or	   sustained	   ventricular	   tachycardia	   of	  
left	   bundle-­‐branch	   morphology	   with	   superior	   axis	  
(negative	  or	  indeterminate	  QRS	  in	  leads	  II,	  III,	  and	  aVF	  
and	  positive	  in	  lead	  aVL).	  
Nonsustained	   or	   sustained	   ventricular	   tachycardia	   of	  
RVOT	   configuration,	   LBBB	   morphology	   with	   inferior	  
axis	  (positive	  QRS	  in	  leads	  II,	   III,	  and	  aVF	  and	  negative	  
in	   lead	   aVL)	   or	   of	   unknown	   axis>500	   ventricular	  
extrasystoles	  per	  24h	  (Holter).	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V.	  Family	  history	  
Major	   Minor	  
AC	   confirmed	   in	   a	   first-­‐degree	   relative	   who	   meets	  
current	   Task	   Force	   criteria.	   AC	   confirmed	  
pathologically	   at	   autopsy	   or	   surgery	   in	   a	   first-­‐degree	  
relative	   Identification	   of	   a	   pathogenic	  
mutation	  *	  categorized	   as	   associated	   or	   probably	  
associated	  with	  AC	  in	  the	  patient	  under	  evaluation.	  
History	  of	  AC	  in	  a	  first-­‐degree	  relative	  in	  whom	  it	  is	  not	  
possible	  or	  practical	   to	  determine	  whether	   the	   family	  
member	  meets	   current	   Task	   Force	   criteria	  Premature	  
sudden	  death	  (<35	  years	  of	  age)	  due	  to	  suspected	  AC	  
in	   a	   first-­‐degree	   relative	   AC	   confirmed	   pathologically	  
or	   by	   current	   Task	   Force	   criteria	   in	   second-­‐degree	  
relative.	  
	   	  
VI.	  Genetics	  
	   	  
Five	   genes	   encoding	   important	   desmosomal	   proteins	   are	   thought	   to	   account	   for	   disease	   in	   up	   to	   70%	   of	  
patients.	  A	  number	  of	  non-­‐desmosomal	  gene	  mutations	  have	  been	  associated	  with	  AC.	  
The	  presence	  of	  a	  pathogenic	  mutation	  associated	  or	  probably	  associated	  with	  AC	  in	  an	  individual	  with	  clinical	  
suspicion	  of	  the	  disease.	  
	   	  
Table 2 | 2010 Task Force Criteria for the Diagnosis of AC modified from Marcus et al 2010 7. 
AC, arrhythmogenic right ventricular cardiomyopathy/dysplasia; aVF, augmented voltage unipolar left foot 
lead; aVL, augmented voltage unipolar left arm lead; BSA, body surface area; ECG, electrocardiogram; LBBB, 
left bundle branch block; MRI, magnetic resonance imaging; PLAX, parasternal long-axis view; PSAX, 
parasternal short-axis view; RBBB, right bundle branch block; RV, right ventricular; RVOT, right ventricular 
outflow tract; SAECG, signal-averaged electrocardiogram. 
	  
1.7 New	  proposed	  diagnostic	  criteria	  
Diagnosis	  and	  treatment	  of	  AC	  remain	  major	  challenges	  of	  modern	  cardiology.	  
Novel	   clinical	   tools	   available	   for	   the	   diagnosis	   of	   AC	   include	   contrast-­‐enhanced	   cardiac	  
MRI,	  and	  electroanatomical	  mapping.	  	  
Cardiac	   MRI	   is	   increasingly	   used	   to	   provide	   noninvasive	   tissue	   characterization	   of	   the	  
ventricular	  myocardium.	   In	   addition	   to	   identification	   of	   RV	   involvement,	   this	   technique	  
can	   help	   to	   identify	   even	   early	   or	   minor	   LV	   involvement,	   in	   the	   absence	   of	  
morphofunctional	   abnormalities	   detected	   by	   echocardiography.	   Electroanatomical	  
mapping	   can	   be	   used	   to	   identify	   the	   abnormal	   low-­‐voltage	   areas,	   which	   have	   been	  
demonstrated	   consistently	   in	   endomyocardial	   biopsies	   to	   correspond	   with	   the	   loss	   of	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electrically	   active	   myocardium	   caused	   by	   fibrofatty	   scarring.	   Systematic	   percutaneous	  
catheter	  mapping	   of	   the	   epicardium	   in	   patients	  with	   AC	   in	  whom	   endocardial	   ablation	  
failed	   confirmed	   an	   observation	   made	   by	   pathologists—that	   fibrofatty	   replacement	  
(electroanatomical	  scarring)	  is	  more	  extensive	  on	  the	  epicardial	  than	  the	  endocardial	  side.	  
However,	  electroanatomical	  mapping	  is	  invasive	  and	  performed	  only	  in	  selected	  patients	  
with	  suspected	  AC	  and	  ventricular	  arrhythmias	  of	  RV	  origin	  for	  differential	  diagnosis	  with	  
idiopathic	   RV	   outflow	   tract	   tachycardia,	   and	   to	   guide	   catheter	   ablation	   of	   the	  
arrhythmogenic	  substrate.	  
New	   diagnostic	   criteria	   become	   necessary:	   plakoglobin	   (PG)	   mislocalization	   from	  
intercalated	  disk	  could	  represent	  a	  good	  candidate	  to	  become	  a	  new	  diagnostic	  tool	  60,	  61,	  
but,	  unfortunately,	  it	  presents	  persisting	  disadvantages.	  First	  of	  all	  immunohistochemistry	  
localization	  can	  only	  be	  performed	  on	  bioptic	  or	  autoptic	  samples,	  and	  secondary	  the	  test	  
is	   not	   specific	   for	   AC	   as	   it	   is	   also	   positive	   in	   patients	   with	   sarcoidosis	   and	   giant	   cell	  
myocarditis	  62.	  	  
Non-­‐invasive	   biomarkers	   are	   also	   actively	   investigated	   and	   BIN1	   has	   recently	   been	  
proposed	  as	  a	  new	  circulating	  biomarker	  that	  correlates	  with	  HF	  and	  predicts	  arrhythmias	  
in	  AC	  patients	  63.	  
Nevertheless	   the	   ElectroAnatomic	   voltage	   Mapping	   (EAM)	   has	   recently	   given	   highly	  
performing	   results	   in	   the	   setting	   of	   suspected	   AC	   and	   of	   unexplained	   ventricular	  
arrhythmias.	  This	  method	  shows	  high	  sensitivity	  and	  sensibility	  in	  recognising	  low-­‐voltage	  
regions,	  which	  reflects	  the	  fibro-­‐adipose	  replacement	  of	  the	  myocardium	  (Figure	  6)	  64,	  65.	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Figure 6 | Noninvasive and invasive findings in a representative patient with abnormal RV 
electroanatomic voltage map.66 
A, Twelve-lead ECG showing inverted T waves from V1 to V4 and a premature ventricular beat with a left 
bundle branch block/superior axis morphology. B, Two-dimensional echocardiographic apical view showing 
severe RV dilatation. C, Right anterior oblique view of RV bipolar voltage map showing low-voltage values 
(red indicates <0.5 mV) in anteroinfundibular, inferobasal, and apical regions. D, EMB sample showing 
massive myocardial atrophy and fibrofatty replacement (trichrome; magnification ×6). E, Close-up showing 
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1.8 Treatment	  
As	  the	  causal	  mechanisms	  of	  AC	  are	  poorly	  understood,	  it	  is	  difficult	  to	  define	  a	  standard	  
therapeutic	  approach.	  The	  treatment	  is	  essentially	  empiric	  and	  based	  on	  patient’s	  clinical	  
manifestations,	  arrhythmic	  risk	  and	  compliance.	  Every	  therapeutic	  methodology	  has	  the	  
goal	   to	   prevent	   life-­‐threatening	   arrhythmias	   and	   SCD.	   A	   therapy	   to	   reverse	   the	   fibro-­‐
adipose	  substitution	  is	  not	  available.	  Possible	  interventions	  are	  lifestyle	  changes,	  such	  as	  
avoiding	   strenuous	  exercise,	   antiarrhythmic	  drug	   administration,	   surgery	   and	  placing	  of	  
an	   Implantable	   Cardioverter	   Defibrillator	   (ICD).	   Finally,	   heart	   transplantation	   should	   be	  
considered	   in	   case	   of	   patients	  with	   progressive	  HF	   and	   refractory	   recurrent	   ventricular	  
arrhythmias	  67.	  
Ablation	  therapy	  is	  often	  carried	  out	  during	  electrophysiological	  studies,	  with	  the	  aim	  of	  
destroy	  areas	  of	  re-­‐entry	   in	  the	  myocardium	  that	   lead	  to	  VTs,	  by	  burning	  the	  foci	  of	  re-­‐
entry	  away.	  In	  the	  same	  occasion	  may	  be	  done	  a	  diagnostic	  biopsy	  in	  order	  to	  determine	  
the	  clinical	  diagnosis.	  It	  may	  be	  considered	  as	  a	  possible	  ICD	  alternative	  68.	  
Since	   1990's,	   pharmacological	   treatment	   for	   serious	   arrhythmias	   has	   been	   replaced	   by	  
lCD	   implantation.	   lCD	   is	   a	   battery-­‐operated	   system	   that	   recognizes	   VTs	   and	   VFs	   and	  
terminates	  them,	  preventing	  SCD.	  Rare	  problems	  occur	  with	  ICD,	  including	  device	  failure	  
issues,	  infections	  69	  and	  surgical	  complications	  70.	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Figure 7 | Stratification risk in SCD prevention and for ICD implant 71. 
SCD risk stratification. Top, Pyramid profile currently used to identify those patients at highest risk for SCD 
who are potential candidates for ICD. BP indicates blood pressure; LVH, LV hypertrophy; NSVT, non-
sustained VT. Sustained ventricular tachyarrhythmias have been reported in a significant minority of patients 
(≈10%) over the short term after alcohol septal ablation. Bottom, Direct relation between magnitude of LV 
hypertrophy (maximum [max] wall thickness by echocardiography) and SD risk. Mild hypertrophy conveys 
generally lower risk; extreme hypertrophy (wall thickness ≥30 mm) conveys the highest risk as a marker for 
SCD. 
	  
Clinical	   studies	   have	   identified	   a	   number	   of	   possible	   predictors	   of	   arrhythmic	   risk	   72-­‐76	  
such	  as:	  aborted	  sudden	  death,	  unexplained	  syncope	  and	  unstable	  sustained	  ventricular	  
tachycardia,	  severe	  dilation/dysfunction	  of	  the	  right	  ventricle,	  left	  ventricle	  or	  both,	  early	  
onset	   of	   the	   disease,	   extent	   of	   bipolar	   right	   ventricle	   low	   voltage	   area,	   ventricular	  
fibrillation	  inducibility	  at	  programmed	  electrical	  stimulation,	  low	  Tricuspid	  Annulus	  Plane	  
Systolic	  Excursion	  (TAPSE).	  
As	   for	   the	   bi-­‐ventricular	   structural	   degeneration,	   no	   therapies	   are	   present	   with	   the	  
exception	  of	  heart	  transplantation	  in	  patients	  with	  end-­‐stage	  HF	  77.	  
	   	  




microRNAs	  (miRNAs)	  constitute	  a	   large	  family	  of	  21-­‐25	  nucleotides,	  endogenous,	  single-­‐
stranded	   RNA	   molecules	   78,	   evolutionarily	   conserved	   among	   many	   distantly	   related	  
species;	   this	   suggest	   that	   miRNAs	   play	   a	   very	   important	   role	   in	   essential	   biological	  
processes.	  	  
The	   first	   miRNAs	   (lin-­‐4,	   let-­‐7)	   were	   identified	   in	   C.	   elegans	   (Reinhart,	   Weinstein	   et	   al.	  
2002)	  when	  they	  were	  called	  small	  temporal	  RNAs	  (stRNA).	  The	  lin-­‐4	  and	  let-­‐7	  stRNAs	  are	  
now	  recognized	  as	  the	  founding	  members	  of	  an	  abundant	  class	  of	  tiny	  RNAs	  (e.g.	  miRNA,	  
siRNA,	  coRNA,	  ncRNA)	  (Figure	  8).	  
	  
Figure 8 | Breakthrough discoveries in miRNA biology 79. 
Time line indicating seminal discoveries in miRNA biology with a special focus on the cardiovascular field. 
	  
miRNAs	   are	   involved	   in	   several	   biological	   processes,	   including	   development	   80,	  
differentiation	   81,	   apoptosis	   82	   and	   cell	   cycle	   regulation	   83.	   miRNAs	   have	   also	   recently	  
emerged	  as	  key	  regulators	  of	  the	  networks	   involved	  in	  the	  Toll	  Like	  Receptors	  signalling	  
pathways	   where	   they	   act	   as	   activators	   of	   the	   immune	   system	   to	   provide	   both	   host	  
defence	   against	   pathogen	   infections	   and	   mediators	   of	   an	   increased	   metastatic	  
proliferation	  in	  tumors	  84	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It	  has	  been	  shown	  that	  misregulation	  at	  any	  of	  these	  processes	  due	  to	  abnormal	  miRNAs	  
expression	   or	   mutations	   can	   potentially	   lead	   to	   disease	   85	   or	   cancer	   86.	   Moreover	  
pathological	   processes	   can	   induce	   the	   increase	   or	   the	   decrease	   of	   some	  miRNAs,	   as	   it	  
occurs	  in	  myocardial	  infarction	  (MI).	  In	  fact,	  D’Alessandra	  et	  al.	  demonstrated	  that	  miR-­‐1,	  
miR-­‐133a,	  miR-­‐133b	  and	  miR-­‐499-­‐5p	  were	  highly	  expressed	  in	  MI	  patients,	  while	  mir-­‐122	  
and	  miR-­‐375	  were	  reduced	  87.	  
In	   addition	  miRNAs	   have	   been	   reported	   to	   influence	   even	   gene	   expression	   by	   directly	  




miRNA	  biogenesis	   starts	  with	   transcription	   in	   the	  nucleus	   92	  by	  RNA	  polymerase	   II	   93	   to	  
form	  primary	  miRNA	  transcripts	  (pri-­‐miRNA)	  94.	  	  
Many	   pri-­‐miRNAs	   are	   polyadenylated	   and	   have	   a	   5’	   7-­‐methylguanylate	   cap	   95.	   Usually,	  
one	  miRNA	  gene	  codes	  for	  a	  single	  miRNA,	  but	  there	  are	  also	  miRNAs	  that	  are	  clustered	  
together	  and	  transcribed	  as	  one	  transcript	  96.	  	  
	  A	  typical	  human	  pri-­‐miRNA	  consists	  of	  one	  or	  more	  hairpin	  structures,	  and	  each	  hairpin	  
has	  a	  stem	  of	  33	  base-­‐pairs,	  a	  terminal	  loop,	  and	  two	  upstream	  and	  downstream	  single-­‐
stranded	  flanking	  segments	  97.	  	  
The	   pri-­‐miRNA	   is	   cleaved	   by	   the	   so	   called	   “microprocessor	   complex”	   consisting	   of	   an	  
RNase	  III	  enzyme,	  Drosha,	  and	  the	  DiGeorge	  Critical	  Region	  8	  (DGCR8)	  98.	  	  
The	  product	  of	  this	  cleavage	  is	  the	  precursor	  miRNA	  (pre-­‐miRNA),	  which	  is	  approximately	  
70	  bp	  long,	  with	  a	  3’	  overhang	  of	  2	  nucleotides,	  and	  that	  is	  exported	  from	  the	  nucleus	  to	  
the	  cytoplasm	  by	  Exportin-­‐5	  in	  a	  RanGTP	  dependent	  manner	  99.	  Exportin-­‐5	  recognizes	  the	  
pre-­‐miRNA	  and	  binds	  properly	   the	  pre-­‐miRNA	  only	  according	   its	   length	   (minimal	  16	  bp)	  
and	  its	  single-­‐stranded	  flanking	  regions	  100.	  
In	   the	   cytoplasm	   another	   member	   of	   the	   RNase	   III	   family,	   Dicer,	   cleaves	   off	   the	   pre-­‐
miRNA	   loop	  and	  generates	  an	  approximately	  22-­‐nucleotide	  miRNA	  duplex	  92,	  containing	  
the	  guide	  strand	  (mature	  miRNA)	  and	  the	  passenger	  strand	  (miRNA*).	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After	  cleavage,	  the	  mature	  miRNA	  duplex	  is	  loaded	  into	  a	  protein	  of	  the	  Argonaute	  (Ago)	  
family,	  usually	  Argonaute	  2	  (Ago2),	  that	  will	  in	  turn	  recruit	  the	  other	  elements	  of	  the	  RNA-­‐
induced	  silencing	  complex	  (RISC).	  Upon	  loading,	  the	  miRNA*	  is	  degraded,	  while	  the	  guide	  
strand	  will	  stay	  tethered	  to	  Argonaute	  and	  mediate	  target	  recognition.	  
It	   is	   believed	   that	   from	   each	   pre-­‐miRNA,	   only	   one	   of	   the	   duplex	   strands	   is	   able	   to	   be	  
functionally	  incorporated	  into	  Ago2	  101,	  while	  miRNA*	  is	  degraded.	  	  
As	   of	   release	   19	   of	   miRBase	   (http://www.mirbase.org/),	   all	   mature	   forms	   are	   now	  
annotated	  as	  5p	  for	  the	  mature	  form	  on	  the	  5’	  arm	  of	  the	  hairpin	  and	  3p	  for	  the	  mature	  
form	   on	   the	   3’	   arm	   of	   the	   hairpin,	   regardless	   of	   their	   relative	   expression	   level	   in	   the	  
conditions	  profiled	  102.	  	  
The	   canonical	   mechanism	   of	   miRNA-­‐mediated	   gene	   regulation	   occurs	   at	   the	  
posttranscriptional	   level,	   by	   targeting	   the	   3’	   untraslated	   region	   (UTR)	   of	   an	  mRNA	   and	  
inhibiting	  protein	  production	  103.	  miRNAs	  have	  also	  rarely	  shown	  to	  target	  the	  5’UTR	  and	  
the	  open	  reading	  frame	  (ORF)	  binding	  site	  to	  regulate	  mRNA	  expression	  104,	  105.	  	  
	  
2.3 Circulating	  miRNAs	  
In	  2008,	  two	  different	  groups	  demonstrated	  that	  miRNAs	  are	  present	  at	  detectable	  levels	  
in	   humans’	   serum	   and	   plasma	   106,	   107.	   They	   also	   illustrated	   that	   circulating	  miRNAs	   are	  
very	   stable	   and	   could	   tolerate	   multiple	   freeze-­‐thaw	   cycles,	   long	   periods	   of	   storage,	  
extreme	  pH	  conditions,	  and	  showed	  resistance	  to	  RNase	  A	  digestion.	  	  
Since	   2008	   has	   been	   shown	   that	   circulating	   miRNAs	   can	   be	   packed	   in	   exosomes	   108,	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2.4 miRNA	  as	  biomarkers	  
Circulating	  miRNAs	  retain	  a	  number	  of	  characteristics	  that	  make	  them	  ideal	  biomarkers:	  
stability	   under	   various	   conditions,	   the	   possibility	   to	   be	   detected	   through	   non-­‐invasive	  
methods,	   to	   easily	   measure	   them	   with	   high	   sensitivity	   and	   specificity	   using	   methods	  
among	  which	   qRT-­‐PCR	   is	   the	  most	   used	   107.	   Since	   their	   levels	  may	   significantly	   change	  
upon	  several	  stimuli,	  circulating	  miRNAs	  have	  been	  proposed	  as	  diagnostic	  biomarkers	  in	  
different	   pathologic	   conditions,	   such	   as	   cancer	   112,	   cardiovascular	   disease	   113,	   drug	  
induced	   liver	   injury	   114,	   115,	  diabetes	   116,	  hepatitis	   117,	   118	  and	  sepsis	   119.	  The	  mechanisms	  
underlying	   miRNAs	   release	   into	   the	   bloodstream	   are	   still	   unknown	   and	   are	   currently	  
being	  investigated	  120.	  Recent	  reports	  have	  described	  the	  diagnostic	  potential	  of	  miRNAs	  
in	  cardiologic	  diseases	  such	  as	  HF	  121,	  Myocardial	  Infarction	  (MI)	  87,	  and	  Atrial	  Fibrillation	  
(AF)	  122,	  123.	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3. Cardiac	  Mesenchymal	  Stromal	  Cells	  (C-­‐MSCs)	  
	  
3.1 Mesenchymal	  Stromal	  Cells	  (MSCs)	  
Mesenchymal	   Stromal	   Cells	   (MSCs)	   are	   adult,	   fibroblast-­‐like	   multipotent	   cells	  
characterized	   by	   the	   ability	   to	   differentiate	   into	   tissues	   of	   mesodermal	   origin,	   such	   as	  
adipocytes,	  chondroblasts,	  osteoblasts	  124,	  125	  and	  also	  in	  endothelial	  cells,	  contributing	  to	  
the	   revascularization	   of	   ischemic	   tissue.	   Several	   studies	   have	   shown	   that	   both	   MSCs	  
differentiation	   in	   many	   tissues	   and	   their	   function	   can	   lead	   to	   the	   repair	   of	   damaged	  
organs	  and	   the	   reconstitution	  of	   the	   immune	   system.	   First	   identified	  and	   isolated	   from	  
the	   bone	   marrow	   (BM-­‐MSCs)	   can	   now	   be	   expanded	   from	   a	   variety	   of	   other	   tissues	  
including	   adipose	   tissue	   126,	   umbilical	   cord	   blood,	   liver	   127,	   skin,	   tendon,	   muscle,	   and	  
dental	  pulp	   128.	  MSCs	  can	  be	   isolated	  based	  on	   their	  ability	   to	  adhere	   to	  plastic	   culture	  
dishes,	  and	  they	  are	  capable	  of	  significant	  expansion	  by	  consecutive	  in	  vitro	  passaging	  125	  
of	   the	   so-­‐called	   “colony	   forming	   units”.	   They	   are	   characterized	   by	   the	   expression	   of	  
mesenchymal	   surface	   antigens	   such	   as	   CD44,	   CD105,	   CD29,	   and	   CD90.	   It	   has	   been	  
reported	   that	   MSCs,	   in	   vitro,	   secrete	   various	   bioactive	   molecules	   anti-­‐apoptotic,	  
immunomodulatory,	  angiogenic,	  anti-­‐scarring,	  and	  chemoattractant	  properties,	  while,	   in	  
vivo,	   interact	  with	   immune	   cells	   of	   the	   innate	   and	   adaptive	   system,	   in	   order	  modulate	  
them	  129.	  The	  ability	  of	  MSCs	  to	  perform	  all	  these	  functions,	  opened	  the	  horizons	  on	  their	  
potential	  use	  in	  the	  clinical	  setting	  and	  in	  particular	  in	  the	  field	  of	  regenerative	  medicine.	  
	  
3.2 Cardiac	  Mesenchymal	  Stromal	  Cells	  (C-­‐MSCs)	  
In	   2010,	   Rossini	   et	   al.,	   firstly	   identified	   and	   characterized	   a	   population	   of	   cardiac	  
mesenchymal	  stromal	  cells	  (C-­‐MSCs)	  isolated	  from	  adult	  human	  auricles	  130.	  	  
In	  a	  normal	  adult	  heart,	  cardiomyocytes	  represent	  only	  30%	  of	  the	  total	  cell	  number.	  The	  
remaining	  70%	  consists	  of	  other	  cells,	  among	  which	  C-­‐MSCs	  are	  the	  vast	  majority	  131.	  C-­‐
MSCs	   play	   a	   crucial	   role	   in	   maintaining	   normal	   cardiac	   function,	   as	   well	   as	   in	   cardiac	  
remodelling	  during	  pathological	  conditions	  132.	  In	  2015,	  for	  the	  first	  time	  Sommariva	  et	  al.	  
133	   attribute	   C-­‐MSCs	   a	   role	   in	   AC	   adipose	   substitution	   in	   human	   hearts.	   The	   group	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provided	  evidence	  that	  in	  AC	  patient’s	  hearts	  cells	  differentiating	  into	  adipocytes	  express	  
mesenchymal	   markers.	   C-­‐MSCs	   isolated	   from	   human	   AC	   hearts	   express	   desmosomal	  
genes	  and	  are	  more	  prone	  than	  C-­‐MSCs	   from	  control	  hearts	  not	  only	   to	  accumulate	   fat	  
(lipogenesis),	  but	   to	   specifically	  differentiate	   into	  adipocytes.	  Moreover,	  C-­‐MSCs	  exhibit	  
evidence	  of	  PG	  nuclearization	  and	  Wnt	  pathway	  inhibition	  29.	  	  
	  
	  AIMS	  OF	  THE	  STUDY	  
	  
Diagnosis	   of	   AC	   is	   challenging	   because	   of	   the	   broad	   spectrum	  of	   phenotypic	   variations	  
and	   often	   could	   be	   performed	   later	   than	   the	   onset	   of	   the	   disease.	   Diagnostic	   criteria	  
follow	   the	  Marcus’	   guidelines7:	   they	   rely	   on	   this	   scoring	   system	  based	   on	   “Major”	   and	  
“Minor”	   categories.	   Despite	   categories	   specificity,	   they	   are	   not	   so	   sensitive	   in	   the	  
recognition	  of	  AC.	  In	  addition,	  other	  arrhythmic	  pathologies,	  which	  share	  AC	  phenotype,	  
make	  the	  diagnosis	  even	  more	  difficult.	  
Moreover	   the	   lack	   of	   sensible	   and	   specific	   biomarkers	   for	   an	   early	   and	   non-­‐invasive	  
diagnosis,	   could	   lead	   to	   a	  not	   so	  easy	   recognition	  of	   the	  early	   stages	  of	   the	  pathology.	  
Early	   diagnosis	  made	   through	   a	   low	   cost	   and	   non-­‐invasive	   diagnostic	   test	  may	   be	   life-­‐
saving	  for	  many	  AC	  patients.	  
At	   the	   best	   of	   our	   knowledge	   no	   previous	   studies	   investigating	   miRNAs	  
expression/regulation	  in	  AC	  are	  present	  in	  the	  literature.	  
This	  study	  is	  focused	  on	  the	  recognition	  of	  circulating	  miRNAs	  associated	  with	  AC,	  which	  
can	  be	  helpful	  in	  AC	  diagnosis	  and	  their	  involvement	  in	  the	  onset	  and	  progression	  of	  the	  
disease.	  
In	  this	  study	  we	  aimed:	  	  
1. To	  screen	  the	  level	  of	  expression	  of	  miRNAs	  in	  plasma	  samples	  of	  AC	  and	  non-­‐AC	  
male	  subjects.	  
2. To	   assess	   the	   specificity	   of	   potential	   miRNAs	   in	   diagnosing	   AC.	   In	   particular	   to	  
identify	   the	   differential	   expression	   of	   plasma	  miRNAs	   in	   AC	   patients	   vs.	   healthy	  
controls	  (HC)	  and/or	  patients	  with	  ventricular	  arrhythmias	  of	  different	  aetiologies:	  
idiopathic	   ventricular	   arrhythmias	   (IVT)	   and	   patients	   with	   ischemic	   ventricular	  
arrhythmias	  (IC).	  	  
3. To	  evaluate	  a	  possible	  correlation	  between	  miRNAs	  expression	  and	  the	  severity	  of	  
the	  disease	  in	  terms	  of	  ventricular	  function	  and	  fibro-­‐adipose	  replacement	  of	  the	  
myocardium	   by	   means	   of	   ElectoAnatomic	   voltage	   Mapping	   [EAM]	   and	   Late	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Gadolinium	   Enhancement	   (LGE)	   detected	   by	   Contrast	   Enhancement	   Cardiac	  
Magnetic	  Resonance	  (CE-­‐CMR)	  
4. To	   assess	   in	   cardiac	   stromal	   mesenchymal	   cell	   cultures	   how	   different	   levels	   of	  
expression	  of	  the	  identified	  miRNAs	  may	  regulate	  the	  onset	  and	  progression	  of	  the	  
fibro-­‐adipogenesis.	  
	   	  
	  MATERIALS	  &	  METHODS	  
	  
4. Study	  Population	  
From	   September	   2014	   to	   September	   2015	   all	   consecutive	   patients	   referred	   to	   our	  
Arrhythmia	   Center	   of	   the	   Cardiologic	   Center	   (Monzino,	   Milan)	   because	   of	   ventricular	  
arrhythmias	  were	  enrolled	  in	  the	  present	  study.	  
In	  the	  present	  study	  a	  total	  of	  114	  male	  subjects	  were	  enrolled:	  35	  patients	  affected	  by	  
AC,	  35	  were	  HC,	  20	  were	  affected	  by	  IVT	  and	  24	  were	  affected	  by	  IC.	  
	  
The	  overall	  population	  was	  divided	  in	  four	  groups:	  
Goup	  A:	  	  patient	  affected	  by	  AC	  with	  a	  history	  of	  ventricular	  arrhythmias.	  
Group	  B:	  patients	  with	   idiopathic	   ventricular	   tachycardia	   (IVT)	   (Right	  or	   Left	  Ventricular	  
Outflow	  Tract	  tachycardia	  (RVOT/LVOT).	  
Group	  C:	  patients	  with	  ischemic	  ventricular	  tachycardia	  
Group	  D:	  healthy	  controls/donor	  
Patients	  were	  diagnosed	  with	  AC	  according	  to	  the	  International	  Task	  Force	  (ITF)	  criteria	  (2	  
major	  criteria	  or	  1	  major	  criterion	  plus	  2	  minor	  criteria	  or	  4	  minor	  criteria).	  Each	  patient	  
with	   a	   suspect	   diagnosis	   of	   AC	   underwent	   intracardiac	   electrophysiological	   study	   to	  
assess	  VT/VF	  inducibility	  as	  well	  high	  density	  EVM.	  
AC	   and	   VT	   patients	   were	   enrolled	   in	   the	   study	   if	   satisfying	   Marcus	   diagnostic	   criteria	  
(Marcus,	  McKenna	  et	  al.	  2010)	  and	  if	  they	  were	  clinically	  considered	  affected	  by	  Right	  or	  
Left	  Ventricular	  Outflow	  Tract	  tachycardia	  (RVOT/LVOT),	  respectively.	  	  
Once	  enrolled	  in	  the	  study,	  from	  each	  patient	  the	  following	  data	  were	  collected:	  -­‐ Detailed	  cardiac	  evaluation	  including	  family	  history	  and	  physical	  examination	  -­‐ 12-­‐lead	  ECG	  recording	  -­‐ 24-­‐hour	  ECG	  Holter	  monitoring	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-­‐ transthoracic	  echocardiography	  -­‐ cardiac	   catheterization	   including	   RV	   and	   left	   ventricular	   (LV)	   cineangiography	   in	  
the	  right	  and	  left	  anterior	  oblique	  view	  -­‐ Coronary	  angiography	  -­‐ RV	  endomiocardial	  biopsies	  when	  indicated	  -­‐ Blood	  samplaes	  for	  RNA	  extraction	  -­‐ Contrast	  Enahanced	  Cardiac	  Magnetic	  Resonance	  -­‐ A	  complete	  electrophysiological	  study	  -­‐ An	  electroanatomic	  voltage	  mapping	  
Our	  Ethical	  Committee	  approved	  the	  study,	  and	  all	  patients	  gave	  their	  written	  informed	  
consent.	   Blood	   samples	  were	   collected	   in	   basal	   condition	   and	   plasma	  was	   obtained	   by	  
centrifugation,	  according	  to	  the	  pertinent	  Italian	  legislation	  and	  Helsinki	  declaration.	  
5. Contrast	  Enhanced	  Cardiac	  Magnetic	  Resonance	  (CE-­‐CMR)	  
Each	  patient	  underwent	  Contrast	  Enhanced	  Cardiac	  Magnetic	  Resonance	  (CE-­‐CMR).	  	  
The	  exam	  was	  performed	  with	  a	  1.5-­‐T	  scanner	  (Discovery	  MR450,	  1.5	  Tesla,	  GE)	  using	  a	  
comprehensive	  dedicated	  protocol.	  
The	  following	  data	  were	  collected:	  	  -­‐ RV	  and	  LV	  volumes	  -­‐ RV	  and	  LV	  function	  -­‐ Presence	  and	  extension	  of	  late	  gadolinium	  enhancement	  deposition.	  	  -­‐ Presence	  bulging	  areas	  -­‐ Evaluation	  of	  RV/LV	  wall	  and	  wall	  motion	  abnormalities	  -­‐ Evaluation	  of	  Fatty	  Infiltration;	  -­‐ Evaluation	  of	  Fibrosis.	  
	  
The	  data,	  including	  post-­‐contrast	  sequences,	  were	  acquired	  according	  to	  the	  following	  
CMR	  study	  protocol:	  
1.	  steady-­‐state	  free	  precession	  sequence	  (true	  fast	  imaging	  in	  steady	  state)	  cine	  loops	  
in	  sequential	  short-­‐axis	  views	  and	  transverse	  long-­‐axis	  views	  of	  RVOT;	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2.	  T1-­‐weighted	  turbo	  spin-­‐echo	  images	  in	  the	  axial	  and	  short-­‐axis	  planes;	  	  
3.	  	  T2-­‐weighted	  short	  tau	  inversion	  recovery	  for	  fat	  suppression.	  
4.	   Ten	   minutes	   after	   administration	   of	   contrast	   agent	   (gadobenate	   dimeglumine,	  
Multihance,	  Bracco,	  0.2	  mmol/kg	  of	  body	  weight),	  2D	  segmented	  fast	  low-­‐angle	  shot	  
inversion	   recovery	   sequences,	   after	   at	   least	  10	  minutes,	  were	  acquired	   in	   the	   same	  
views	   of	   cine	   images,	   covering	   the	   entire	   RV	   and	   LV.	   Considering	   the	   T1	   relaxation	  
times	  of	  the	  tissues	  and	  the	  wash-­‐in	  and	  wash-­‐out	  kinetics	  of	  extracellular	  interstitial	  
contrast	  agents,	  the	  optimized	  T1	  nullifies	  the	  signal	  from	  normal	  myocardium	  in	  the	  
images	   acquired	   10	   minutes	   after	   contrast	   medium	   injection.	   This	   allows	   clear	  
visualization	  of	  the	  DCE	  areas,	  defined	  as	  a	  signal	  intensity	  at	  least	  400%	  higher	  than	  
the	  signal	  from	  normal	  (remote)	  myocardium	  or	  skeletal	  muscle.	  
6. Electrophysiological	  Study	  	  
Before	  the	  electrophysiological	  study,	  all	  antiarrhythmic	  drugs	  were	  discontinued	  to	  allow	  
a	  complete	  wash-­‐out	   (5	  half-­‐lives	  or	  6	  weeks	   for	  amiodarone).	  Programmed	  ventricular	  
stimulation	   protocol	   included	   3	   drive	   cycle	   lengths	   (600,	   500,	   and	   400	   ms)	   and	   3	  
ventricular	   extrastimuli	   while	   pacing	   from	   2	   RV	   sites	   (apex	   and	   outflow	   tract).	  
Programmed	  ventricular	  stimulation	  was	  considered	  positive	  if	  either	  a	  VF	  or	  sustained	  VT	  
(ie,	   one	   that	   lasted	   ≥30	   seconds	   or	   required	   termination	   because	   of	   hemodynamic	  
compromise)	   was	   induced.	   Programmed	   ventricular	   stimulation	   was	   repeated	   after	  
intravenous	  isoproterenol	  infusion	  in	  those	  patients	  with	  effort	  induced	  non	  sustained	  VT.	  
7. Electroanatomic	  Voltage	  Mapping	  and	  Endomiocardial	  Biopsy	  
All	   patients	   underwent	   right	   ventricle	   (RV)	   electroanatomic	   mapping	   performed	   with	  
CARTO	   4	   system	   (Biosense	  Webster)	   during	   sinus	   rhythm.	   At	   least	   150	  mapping	   points	  
were	   sampled	   with	   an	   irrigated-­‐	   tip	   NaviStar	   catheter	   (ThermoCool®	   SmartTouch®	  
Catheter,	  Biosense	  Webster).	  In	  all	  patients,	  we	  used	  a	  catheter	  with	  a	  contact	  sensor	  to	  
provide	   contact	   information	   during	   signal	   acquisition.	   A	   contact	   of	   ≥10	   g	   considered	  
adequate.	   In	   all	   patients	   intracardiac	   echocardiography	   (SoundStar	   3D	   ICE,	   Biosense	  
Webster)	  was	  used	  because	  to	  give	  a	  preliminary	  view	  of	  anatomy	  of	  the	  ventricles	  and	  to	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confirm	   of	   the	   adequateness	   of	   contact	   during	   signal	   acquisition.	   During	   the	   mapping	  
procedure,	  we	  analyzed	  bipolar	   electrograms,	  whereas	  unipolar	  map	  was	  automatically	  
created	  and	  analyzed	  after	   the	  biopsy	  was	   taken,	   and	  before	  biopsy	   report	   knowledge.	  
Reference	  values	   for	   identifying	  distribution	  of	   the	  pathological	  areas	  was	  evaluated	  by	  
dividing	  RV	  voltage	  map	  into	  5	  segments,	  such	  as	  outflow,	  	  
RV	  endomyocardial	  bioptic	   samples	  were	  obtained	   through	   the	   right	   femoral	   vein	  via	  a	  
disposable	  bioptome	  (Bipal,	  Biosense	  Webster)	  introduced	  into	  a	  steerable	  sheath	  (Agilis	  
NxT,	  St.	  Jude	  Medical).	  	  
The	   bioptome	   catheter	   was	   always	   displayed	   into	   the	   CARTO	   4	   system	   thanks	   to	   the	  
Advanced	   Catheter	   Localization	   technology,	   that	   allows	   the	   localization	   of	   all	   catheters	  
inside	   the	   heart	   thanks	   to	   the	   measurement	   of	   changes	   in	   the	   basal	   electric	   range	  
generated	  by	  patches	  initially	  put	  on	  the	  patient’s	  chest	  and	  back.	  	  
We	  were	  able	  to	  visualize	  the	  bioptome	  with	  the	  CARTO	  system	  by	  putting	  a	  small	  screw	  
into	  the	  adapter	  of	  the	  bioptome’s	  handle	  and	  pinching	  it	  with	  a	  couple	  of	  alligator	  clips,	  
creating	  an	  electric	  dipole.	  Connecting	   these	  electric	  cables	   to	   the	  CARTO	  system	  made	  
the	   bioptome	   “visible”	   as	   any	   other	   electrophysiological	   catheter.	   In	   this	  way	  we	  were	  
able	  to	  “triple”	  check	  (with	  fluoroscopy,	  CARTO	  system	  and	  ICE)	  the	  tip	  of	  the	  bioptome	  
before	  sampling	  the	  RV.	  
An	  EMB	  guided	  by	  EVM	  was	  performed	  in	  all	  patients	  who	  had	  an	  abnormal	  bipolar	  map.	  
In	   every	   patient,	   at	   least	   1	   sample	   was	   obtained	   from	   an	   area	   with	   normal	   bipolar	  
electrograms	   and	   one	   from	   an	   area	  with	   pathological	   bipolar	   electrograms.	   In	   patients	  
with	  a	  normal	  bipolar	  EVM,	  biopsies	  were	  gained	  from	  the	  mid	  portion	  of	  the	  right-­‐sided	  
interventricular	  septum.	  The	  sites	  of	  biopsy	  were	  marked	  on	  the	  map.	  The	  sites	  of	  biopsy	  
were	  marked	  on	  the	  map.	  (Figure	  9Figure	  8).	  
The	  biopsy	   report	  was	  correlated	   the	  bipolar	  and	  unipolar	  voltage	  map	  at	   the	  sampling	  
sites	  and	  we	  matched	  the	  EVM	  results	  with	  biopsies.	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Figure 9 | Electroanatomical Voltage Mapping. 
A, Endocardial bipolar voltage map of a patient undergoing endomyocardial biopsy for a suspicion of 
arrhythmogenic right ven- tricular dysplasia/cardiomyopathy; the map is completely normal. B, Endocardial 
unipolar voltage map of the same patient; in this case areas of low voltage (red) are evident at right ventricle 
outflow tract, apex, and peritricuspidalic sites. C, Discordant normal bipolar (yellow) and low-voltage unipolar 
(light blue) electrograms at withdrawal site. D, The biopsy performed at the apex showed fibrofatty 
replacement corresponding to 30% of the whole tissue.  
8. Histology	  and	  Immunohistochemistry	  Analysis	  	  
3	  to	  4	  samples	  were	  obtained	  from	  each	  patient	  for	  histology	  and	  immunohistochemistry	  
analysis.	  	  
The	   analysis	   were	   performed	   by	   the	   Cardiovascular	   Pathology	   Department	   of	   the	  	  
University	   of	   Padova.	   All	   samples	   were	   fixed	   in	   10%	   phosphate-­‐buffered	   formaIin	   and	  
subsequently	   paraffin	   enclosed.	   Serial	   sections	   are	   cut	   and	   stained	   with	   hematoxylin	   -­‐	  
eosin	  and	  trichrome	  Azan	  –	  Mallory.	  
Immunohistochemistry	   for	   the	   characterization	   of	   inflammatory	   infiltrates	   was	  
performed.	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1-­‐2	  tissue	  fragments	  were	  put	  into	  RNA	  later	  in	  order	  to	  investigate	  the	  presence	  of	  viral	  
agents	  using	  a	  molecular	  biology	  approach.	  
In	   patients	   presenting	   histological	   evidence	   of	   fibrofatty	   replacement,	   a	  
histomorphometric	  analysis	  was	  performed	  to	  calculate	  the	  extent	  of	  myocardial	  atrophy	  
and	  fibrofatty	  replacement.	  
9. Plasma	  samples	  
Peripheral	   venous	  blood	  samples	  were	  collected	   in	  6	  ml	  EDTA-­‐coated	  VACUTAINER	  and	  
processed	  immediately.	  Cell-­‐	  and	  platelet-­‐free	  plasma	  was	  prepared	  following	  a	  two-­‐step	  
centrifugation	  protocol.	  Samples	  were	  firstly	  centrifuged	  at	  1.500	  ×	  g	  for	  15’	  at	  4°C.	  The	  
plasma	  samples,	  located	  at	  the	  top	  of	  the	  specimen	  was	  centrifuged	  again	  at	  14.000	  ×	  g	  
for	  15’	  at	  4°C	  to	  obtain	  platelet-­‐poor	  plasma	  and,	  thereafter,	  divided	  in	  400μl	  aliquots	  in	  
2mL	  eppendorf	  tubes	  and	  stored	  at	  -­‐80°C	  until	  use.	  
10. C-­‐MSCs	  isolation	  and	  culture	  
Patients	  with	  a	  suspect	  of	  AC	  underwent	  a	  series	  of	  non-­‐invasive	  tests	  and,	  when	  needed	  
because	  of	  diagnostic	  confirmation,	  an	  endomyocardial	  biopsy	  was	  performed	  in	  the	  area	  
adjacent	   to	   the	   low	   potential	   endomyocardial	   scar	   and	   compared	   to	   endomyocardial	  
fragments	  of	  a	  group	  of	  5	  cadaveric	  donors	  with	  a	  completely	  normal	  heart.	  
The	   specimens	  were	  washed	  with	   phosphate-­‐buffered	   saline	   (PBS;	   Lonza),	   cut	   into	   2-­‐3	  
mm3	  pieces	  and	  incubated	  at	  37°C	  for	  1.5	  hours	  under	  continuous	  agitation	  in	  Ham’s	  F12	  
medium	   containing	   3mg/mL	   collagenase	  NB	   4	   (Serva).	   The	   digestion	   solution	  was	   then	  
filtered	  with	  70μm	  mesh	  nylon	  filters	  (BD-­‐biosciences),	  centrifuged	  at	  400	  x	  g	  for	  10’	  and	  
the	   obtained	   pellet	   was	   re-­‐suspended	   in	   IMDM	  medium	   supplemented	   with	   20%	   FBS	  
Hyclone	  (Euroclone),	  10ng/ml	  basic	  fibroblast	  growth	  factor	  (R&D	  Systems),	  10000	  U/ml	  
Penicilin	  (Invitrogen),	  10000	  µg/ml	  Streptomycin	  (Invitrogen)	  and	  20	  mmol/L	  L-­‐Glutamine	  
(Sigma-­‐Aldrich)	   (T.MES).	   Cells	   were	   seeded	   into	   uncoated	   Petri	   dishes	   (Corning).	   Non-­‐
adherent	  cells	  were	  removed	  after	  24h.	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11. Adipogenic	  differentiation	  
C-­‐MSCs	  were	  cultured	  in	  adipogenic	  induction	  medium	  consisting	  of	  IMDM	  supplemented	  
with	  10%	  FBS	  (Sigma-­‐Aldrich),	  0.5	  mmol/L	  3-­‐isobutyl-­‐1-­‐methylxanthine	  (IBMX),	  1	  µmol/L	  
hydrocortisone	   (HC),	   and	   0.1	   mmol/L	   indomethacin	   (IM)	   (Sigma-­‐Aldrich)	   for	   3	   and	   21	  
days.	  
12. Intracellular	  Lipid	  Staining	  by	  Oil-­‐Red	  O.	  
Oil-­‐Red	  O	   (ORO)	   is	  a	   fat-­‐soluble	  dye	  used	   for	  staining	  of	  neutral	   triglycerides	  and	   lipids.	  	  	  
C-­‐MSC	  were	  stained	  with	  1%	  ORO	  (Sigma-­‐Aldrich)	  solution	  in	  60%	  Isopropanol	  for	  1	  hour	  
after	   5	   minutes	   fixation	   with	   4%	   paraformaldehyde	   in	   phosphate-­‐buffered	   saline.	  
Quantitative	   results	  were	   obtained	   by	   evaluating	   luminance	   of	   the	   255	   red	   channel	   by	  
ImageJ	  program	  (at	  least	  20	  fields	  were	  evaluated	  per	  condition	  per	  patient).	  
Cells	  were	  incubated	  with	  FITC/PE-­‐conjugated	  antibodies	  in	  100µl	  PBS	  after	  detachment	  
with	  0.02%	  EDTA	  solution	  (Sigma-­‐Aldrich)	  and	  analysed	  with	  FACSCalibur	  (BD-­‐Biosciences)	  
flow	   cytometer.	   The	   monoclonal	   antibodies	   used	   in	   order	   to	   confirm	   mesenchymal	  
lineage	   and	   to	   exclude	   endothelial	   and	   hematopoietic	   origin	   are	   the	   following:	   CD44,	  
CD90,	   CD105,	   CD29,CD14,	   CD3,	   CD146,	   CD34,	   CD45.	   Immunogenicity	   of	   the	   cells	   was	  
measured	  through	  the	  marker	  HLA-­‐DR.	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Protein	   AB	   host	  
CD14	   CD14-­‐FITC	  (MφP9)	   Mouse	  IgG2b,	  κ	  
CD29	   Integrin	  β1-­‐PE	  (clone	  MAR4)	   Mouse	  IgG1,	  κ	  
CD31	   PECAM-­‐1-­‐APC	  (clone	  9G11)	   Mouse	  IgG1	  
CD34	   Hematopoietic	   progenitor	   cell	  antigen-­‐PE	  (clone	  581)	   Mouse	  IgG1,	  κ	  
CD44	   H-­‐CAM-­‐PE	  (clone	  G44-­‐26	  )	   Mouse	  IgG2b,	  κ	  
CD45	   L-­‐CA-­‐PE	  (clone	  HI30)	   Mouse	  IgG1,	  κ	  
CD90	   THY1-­‐FITC	  (clone	  5E10)	   Mouse	  IgG1,	  κ	  
CD105	   Endoglin-­‐APC	  (clone	  266)	   Mouse	  IgG1,	  κ	  
CD117	   c-­‐KIT-­‐APC	  (clone	  YB5.B8)	   Mouse	  IgG1,	  κ	  
CD144	   VE-­‐Cadherin-­‐APC	  (clone	  123413)	   Mouse	  IgG2B	  
CD146	   MCAM-­‐FITC	  (clone	  128018)	   Mouse	  IgG1	  
HLA-­‐DR	   HLA-­‐DR-­‐FITC	  (clone	  L243)	   Mouse	  IgG2,	  κ	  
KDR	   VEGF	  R2/KDR	  (clone	  89106)	   Mouse	  IgG1	  
Table 3 | Lists of antibodies used for FACS analysis. 
	  
13. RNA	  extraction	  from	  plasma	  	  
Total	  RNA	  was	  extracted	  from	  400	  µl	  of	  plasma,	  following	  a	  modified	  TRIzol®	  protocol	  for	  
liquid	  samples.	  	  
Samples	  were	   thawed,	   then	  1	  ml	  of	  TRIzol®	   reagent	   (Life	  Technologies)	  was	  added	  and	  
incubated	   for	  5’	   at	  RT	   in	  order	   to	  allow	   the	   complete	  dissociation	  of	   the	  nucleoprotein	  
complex.	   After	   adding	   200	   µl	   of	   chloroform	   for	   each	   sample,	   each	   tube	  was	  mixed	   by	  
inversion	  and	  incubated	  for	  3’	  at	  RT.	  The	  phase	  separation	  was	  achieved	  by	  centrifuging	  
samples	  at	  12,000	  x	  g	  for	  15’	  at	  4°C.	  
The	  aqueous	  phase	  was	  transferred	  to	  a	  new	  tube,	  where	  30	  μg	  of	  glycogen	  (Roche)	  and	  
1	  ml	  of	   isopropanol	  were	  added	  in	  order	  to	  induce	  RNA	  precipitation.	  After	  10’	  at	  room	  
temperature,	  RNA	  samples	  were	  pelleted	  10’	  at	  12,000	  ×	  g,	  washed	  with	  1	  ml	  of	  ethanol	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75%,	  and	  centrifuged	  again	  10’	  at	  12,000	  ×	  g.	  Surnatants	  were	  eliminated	  and,	  after	  a	  5’	  
drying	  step,	  pellets	  were	  resuspended	  in	  52	  μl	  of	  RNAse-­‐free	  water.	  
14. RNA	  extraction	  from	  cells	  
Total	  RNA	  was	  extracted	   from	  pelleted	  cells	  with	  1	  ml	  of	  TRIzol®	   reagent,	   following	   the	  
manufacturer’s	  protocol.	  Total	  RNA	  was	  resuspended	  with	  32μl	  of	  RNase-­‐free	  water	  and	  
then	  quantified.	  
15. miRNAs	  screening	  
TaqMan	  Human	  microRNA	  Card	  Arrays	  A&B	  version	  2.0	  (Life	  Technologies)	  were	  used	  for	  
expression	   screening	   of	   377	   miRNAs,	   conducted	   on	   3	   plasma-­‐derived	   RNA	   samples	  
randomly	  selected	  from	  AC	  and	  3	  gender-­‐	  and	  age-­‐matched	  healty	  controls	  (HC).	  	  
Reverse	  transcription	   (RT)	  and	  pre-­‐amplification	  steps	  were	  performed	  according	  to	   the	  
manufacturer’s	  protocol,	  using	  a	  7900HT	  Fast	  Real-­‐Time	  PCR	  System	  (Life	  Technologies).	  	  
TaqMan	   MicroRNA	   Array	   is	   an	   array	   with	   384	   wells	   per	   card,	   containing	   lyophilized	  
primers	  and	  probes.	  The	  array	  allows	  the	  quantification	  of	  the	  expression	  of	  377	  miRNA.	  4	  
small	   non-­‐coding	   RNA	   controls	   (mammU6),	   2	   additional	   endogenous	   controls,	   and	   a	  
sample	   unrelated	   with	   the	   mammalian	   species,	   are	   respectively	   used	   as	   an	   internal	  
procedure	  control	  and	  negative	  control	  of	  the	  card.	  The	  4	  replicates	  of	  the	  endogenous	  
control	  are	  used	  to	  normalize	  the	  (Cycle	  Threshold)	  Ct	  values	  of	  all	  377	  miRNAs.	  	  
Each	  card	  consists	  of	  8	  ports,	  in	  which	  100	  μl	  of	  sample	  containing	  50	  uL	  of	  Master	  Mix,	  
No	  AmpErase	  UNG,	   49	  μl	   of	  water	  Nuclease-­‐free	   and	   1	   uL	   of	   diluted	   pre-­‐amplified	   are	  
loaded.	  The	  pre-­‐amplification	  step	  is	  useful	  to	  increase	  the	  amount	  of	  respective	  cDNA	  for	  
subsequent	   PCR	   Array	   analysis.	   The	   card	   is	   centrifuged	   2	   times,	   in	   special	   adapters,	   at	  
1,200	   x	   g	   for	   1	  minute.	   The	   card	   is	   loaded	   on	   the	   instrument	   7900	   HT	   Fast	   Real	   Time	  
System	  (Applied	  Biosystem)	  for	  quantitative	  analysis.	  	  
Results	   were	   expressed	   as	   Ct	   levels	   and	   normalized	   to	   the	   median	   Ct	   of	   each	   sample	  
(ΔCt),	   so	   that	   all	   subsequent	   calculations	   were	   independent	   from	   the	   amount	   of	   RNA	  
added	  to	  the	  PCR	  reaction.	  Relative	  expression	  was	  calculated	  using	  the	  comparative	  Ct	  
method	   (2-­‐ΔΔCt).	   All	   miRNAs	   detectable	   in	   all	   3	   samples	   showing	   a	   Ct<30	   were	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considered	  as	  expressed.	  We	  considered	  for	  the	  subsequent	  validation	  phase	  only	  those	  
miRNAs	  whose	   expression	   in	   AC	   patients	   significantly	   differed	   from	   the	  HC	   on	   average	  
more	  than	  2	  folds	  or	  less	  than	  one	  half.	  	  
16. miRNA	  validation	  in	  RNA	  from	  plasma	  and	  cell	  samples	  
All	  the	  following	  steps	  were	  conducted	  by	  qRT-­‐PCR	  using	  single	  TaqMan	  microRNA	  assays	  
(Life	   Technologies),	   accordingly	   to	   manufacturer’s	   instructions,	   and	   calculated	   as	   fold	  
change	  by	  the	  2-­‐∆∆Ct	  method	  (∆Ct,	  ∆∆Ct,	  2-­‐∆∆Ct).	  	  
Since	  no	  RNA	  quantification	  from	  plasma	  sample	  was	  possible,	  the	  same	  volume	  of	  RNA	  
solution	  (2	  µl)	  was	  used	  in	  each	  RT	  assay	  for	  technical	  consistency.	  
Conversely,	   since	   RNA	   quantitation	   from	   cell	   sample	   was	   possible,	   RNA	   samples	   were	  
diluted	  in	  RNAse-­‐free	  water	  at	  the	  concentration	  of	  2.5	  ng/μl	  in	  order	  to	  use	  5ng	  of	  RNA	  
solution	  in	  each	  RT	  assay	  (2	  μl	  of	  RNA	  solution	  each)	  for	  technical	  consistency.	  	  
Profiling	  data	  analysis	  showed	  15	  potential	  normalizers	  that	  exhibited	  strong	  expression	  
in	   all	   samples.	   Among	   these,	  miR-­‐210	  was	   identified	   as	   the	   best	   potential	   normalizers	  
using	   the	   geNorm	   algorithm.	   The	   confirmation	   step	   of	   the	   screening	   results	   was	  
conducted	  on	  the	  same	  samples	  used	  to	   identify	   the	  best	   internal	  normalizer,	  and	  then	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17. Statistical	  analysis	  	  
Quantitative	   results	   are	   expressed	   as	  mean	   ±	   SD,	   or	  mean	   ±	   SEM.	   The	   analysis	   of	   the	  
patients’	   characteristics	  was	   conducted	   using	   the	   Student's	   T	   test	   and	   the	   Fisher	   exact	  
test.	  
Results	  obtained	  with	  the	  TaqMan	  Human	  microRNA	  Card	  Arrays	  A&B	  version	  2.0	  were	  
analysed	  with	  Expression	  Suite	  v1.0.3	  software.	  	  
Comparisons	  of	  parameters	  among	   two	  groups	  were	  made	  by	   the	  unpaired	  Student’s	   t	  
test.	  All	  analysis	  were	  performed	  with	  2-­‐tailed	  t	  test,	  considering	  statistically	  significant	  all	  
values	  of	  p	  <0.05	  using	  the	  Graphpad	  Prism	  5	  software.	  	  
Regression	  analysis	  and	  ROC	  curve	  definition	  were	  calculated	  using	  the	  Graphpad	  Prism	  5	  
software.	  
	   	  
	  RESULTS	  
	  
18. Patients	  characteristics	  
Since	   Arrhythmogenic	   Cardiomyopathy	   (AC)	   is	   a	   rare	   pathology,	   which	   occurs	   with	   a	  
prevalence	  of	  3:1	  in	  males,	  in	  order	  to	  eliminate	  every	  confounding	  variable	  we	  decided	  
to	  analyse	  only	  male	  populations	  of	  both	  patients	  and	  healthy	  controls	  (HC).	  
AC	  patients	  were	  enrolled	  if	  they	  fulfilled	  the	  Marcus	  diagnostic	  Task	  Force	  Criteria	  (two	  
major,	  one	  major	  and	  two	  minor,	  or	  four	  minor)	  (Table	  2)	  7,	  using	  the	  following	  diagnostic	  
tools.	   The	   figures	   (Fig	   10-­‐13)	   are	   representative	   of	   the	   results	   obtained	   in	   the	   patients	  
included	  in	  the	  study	  for	  each	  used	  diagnostic	  criteria.	  
2D-­‐echo,	   due	   to	   its	   accessibility,	   low	   cost	   and	  non-­‐invasiveness	   is	   one	  of	   the	   first	   level	  
diagnostic	   tools	   and	   it	   is	   able	   to	   highlight	  morphological	   and	   functional	   changes	   of	   the	  
heart.	  In	  particular	  we	  considered	  both	  right	  and	  left	  ventricular	  function	  as	  indicated	  by	  
the	  values	  of	  Tricuspid	  Annular	  Plane	  Sistolic	  Excursion	  (TAPSE)	  and	  left	  ventricle	  Ejection	  
Fraction	   (EF).	   Diagnosing	   AC	   in	   patients	   with	  minimal	   right	   ventricular	   abnormalities	   is	  
difficult	   to	   accomplish	   using	   2D-­‐echo,	   therefore	   it	   becomes	   necessary	   using	   other	  
diagnostic	  tools.	  
ECG	   interpretation	   can	   be	   helpful	   in	   AC	   recognition.	   It	   however	   rarely	   represents	   a	  
diagnostic	   tool,	   since	  AC	   patients	   usually	   have	   a	   series	   of	   unspecific	   ECG	   abnormalities	  
such	  as	  T-­‐wave	  inversion	  (Figure	  10,	  red	  arrows),	  ectopic	  beats	  (Figure	  10,	  blue	  arrows),	  S	  
wave	  extension,	  while	   the	  only	   rare	   typical	   ECG	  abnormality	   is	   the	  presence	  of	   ε	  wave	  
(Figure	  10,	  green	  arrows).	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Figure 10 | Typical ECG of a AC patient enrolled in the study.  
Green arrows indicate ε wave, blue arrows indicate ectopic beats, red arrows indicate T-wave inversion. 
	  
In	  addition	  Holter	  monitoring	  identifies	  AC	  rhythm	  disorders,	  in	  which	  arrhythmias	  usually	  
originates	  in	  the	  RVOT,	  showing	  a	  Left	  Bundle	  Branch	  Block	  morphology	  (LBBB),	  or	  from	  
LVOT,	  with	  Right	  Bundle	  Branch	  Block	  (RBBB)	  morphology.	  	  
Furthermore,	  Cardiac	  Magnetic	  Resonance	  (CMR)	  represents	  an	  essential	  diagnostic	  tool,	  
due	  to	  its	  accuracy	  in	  detecting	  characteristics	  cardiac	  lesions,	  which	  cannot	  be	  detected	  
with	  2D-­‐echo.	  Indeed,	  besides	  dilation,	  aneurysms	  formation	  and	  alterations	  in	  kinetics	  of	  
the	  walls	  of	   the	  RV,	   it	   can	  highlight	   the	   thinning	  of	   the	  RV	  wall	  and	   its	   “bulging”	  areas,	  
characterized	  by	  a	  delay	  in	  uptake	  of	  the	  contrast	  agent	  (Figure	  11,	  panel	  A).	  Though,	  not	  
considered	  among	  the	  diagnostic	  criteria,	  CMR	  is	  able	  to	  detect	  adipose	  infiltration,	  which	  
appear	   hyper-­‐intense	   (Figure	   11,	   panel	   B).	   Unfortunately	   patients	   with	   a	   ICD	   cannot	  
undergo	  CMR,	  thus	  limiting	  its	  diagnostic	  power.	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Figure 11 | Typical CMR of a AC patient enrolled in the study.   
Red arrows indicate RV bulging, while blue arrows indicate the hyper-intense region, which shows the fibro-
adipose replacement of the myocardium.  
	  
In	   certain	   cases	  non-­‐invasive	  diagnostic	   tools	  are	  not	   sufficient	   to	  assess	  an	  undeniable	  
diagnosis;	   therefore	   it	   became	   necessary	   to	   perform	   more	   invasive	   procedures.	  
Electrophysiological	   Study	   tests	   the	   inducibility	   of	   malignant	   arrhythmias;	   3D-­‐
ElectroAnatomic	  voltage	  Mapping	  (EAM)	  identifies	  low-­‐potential	  areas	  which	  reflect	  scar	  
tissue,	   that	   correlate,	   in	   AC	   patients,	   with	   fibro-­‐	   and	   fibro-­‐adipose	   replacement	   of	   the	  
myocardium	  59.	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Figure 12 | Example of a Endocardial bipolar voltage mapping of a patient undergoing 
endomyocardial biopsy for a suspicion of arrhythmogenic cardiomyopathy. Low-voltage 
areas are represented in red. 
	  
EAM	   is	   a	   recognized	   tool	   to	   guide	   bioptic	   sampling;	   biopsy	   is	   used	   to	   perform	   a	  
quantitative	  assessment	  of	  residual	  myocardial	  tissue,	  cardiomyocytes	  degeneration	  and	  
fibro-­‐adipose	  substitution	  (Figure	  13).	  	  
	  
Figure 13 | Example of an endomyocardial biopsy of an our AC patient: histological 
preparation of a bioptic sample acquired in the pathological area, for diagnostic purposes.  
Courtesy of Basso C, Thiene G, Cardiovascular Pathology, University of Padua 
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Typically,	   the	  appearance	  of	  signs	  and	  symptoms	  occurs	   in	  a	  sequential	  manner.	   In	   late	  
phases	  fibro-­‐adipose	  substitution	  may	  proceed	  to	  severe	  RV	  dysfunction,	  and	  further	  to	  




Figure 14 | Image of an explanted heart of an AC patient enrolled in the study. 
RV wall appears thin and translucent. Adipose substitution is visible and prominent. A high-voltage ICD lead 
positioned across the tricuspid valve in the right ventricular chamber is shown. 
	  
From	  September	  2014	  to	  September	  2015	  a	  total	  of	  114	  male	  subjects	  were	  enrolled	  in	  
the	  study	  after	  having	  signed	  a	  written	  informed	  consent.	  	  
The	  study	  population	  was	  grouped	  as	  follows:	  1. 35	  AC	  patients,	  strictly	  adherent	  to	  the	  Marcus’	  Task	  Force	  Criteria;	  2. 35	  male	  age-­‐matched	  HC	  donors.	  	  3. 20	  patients	  affected	  by	   idiopathic	  ventricular	   tachycardia	  RVOT/LVOT	   (IVT),	  according	  to	  the	  current	  guidelines.	  4. 24	  patients	  affected	  by	  ischemic	  cardiomyopathy	  and	  ventricular	  tachycardia	  (IC)	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Patients	   n	   Age	  (mean±sd)	   p	  
AC	   35	   51±12	   ns	  
IC	   24	   63±14	   ns	  
IVT	   20	   47±12	   ns	  
HC	   35	   47±12	   ns	  
Table 4 -  Participants to the study. 
Table show all patients and HC which participated to the study. Numbers and ages are represented. A t 
student test recognized no significant difference between the age distribution. 
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19. miRNA	  screening	  
In	  order	   to	   further	   improve	   the	  diagnostic	   recognition	  of	  AC,	  we	  decided	   to	   investigate	  
the	  plasma	  miRNA	  signature	  in	  our	  cohorts	  AC	  patients.	  
We	   firstly	   conducted	   a	   screening	   of	   circulating	   miRNAs	   on	   AC	   and	   NON-­‐AC	   plasma	  
samples.	   In	  particular	   the	  expression	  of	   377	  miRNAs	   in	  plasma	   from	  3	   symptomatic	  AC	  
patients	  and	  3	  age-­‐matched	  healthy	  controls	  (HC)	  was	  evaluated	  using	  TaqMan	  Arrays	  A.	  	  
135	  miRNAs	   were	   found	   to	   be	   expressed	   in	   all	   screened	   plasma	   samples	   ((Figure	   15).	  
Comparison	  of	  expression	  between	  samples	  was	  made	  using	  global	  mean	  normalization.	  
5	   miRNAs	   resulted	   differentially	   expressed	   in	   AC	   vs	   HC	   according	   to	   empirically	   set	  
thresholds:	  fold	  decrease	  <	  0.5,	  fold	  increase	  >	  2	  with	  p<0.05	  ((Figure	  15).	  	  
In	   a	   further	   analysis,	   giving	   the	   low	   number	   of	   patient’s	   plasma	   samples	   used	   in	   the	  
screening,	   the	  possible	  bias	  of	   selection	  of	   the	  patients	  and	   the	   relative	   low	  number	  of	  
miRNAs	   found	   to	   be	   regulated,	   we	   decided	   to	   include	   in	   the	   validation	   process	   the	   2	  
miRNAs	   (miR-­‐139-­‐5p	   and	   miR-­‐15b)	   whose	   p	   value	   was	   close	   to	   0.05	   (p=0.058	   and	  
p=0.067,	   respectively)	   and	   the	   miRNAs	   regulated	   just	   behind	   the	   threshold	   of	   2	   fold	  
increase	  (1.9	  fold)	  ((Figure	  15).	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(Figure 15 | Volcano plot illustrating miRNAs potentially regulated after TaqMan Card Array. 
Volcano plot shows Taqman Array results. In the graph are represented all dots indicating the fold value of 
each miRNA. Dots indicated with blue arrows were further tested in the validation step. Red line indicate the 
minimum significance considered (p=0.05). 
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20. miRNA	  validation	  
The	   potentially	   identified	   miRNAs	   (miR-­‐320a,	   miR-­‐532-­‐3p,	   miR-­‐126,	   miR-­‐30b,	   miR-­‐30c,	  
miR-­‐140-­‐5p,	  miR-­‐139-­‐5p	  and	  miR-­‐15b)	  were	  subsequently	  tested	  by	  single	  qRT-­‐PCR	  in	  the	  
plasma	   of	   a	   second	   cohort	   of	   18	   patients	   (9	   patients	   with	   AC	   and	   9	   HC)	   in	   order	   to	  
validate	  the	  previous	  results	  and	  to	  identify	  which	  miRNAs	  might	  be	  used	  as	  normalizers.	  	  
miR-­‐210	  demonstrated	  a	  strong	  and	  stable	  expression	  in	  both	  groups	  and	  therefore	  was	  
chosen	  as	  normalizer.	  ((Figure	  15).	  
miR-­‐532-­‐3p,	  miR-­‐126,	  miR-­‐30b,	  miR-­‐30c,	  miR-­‐140-­‐5p,	  miR-­‐139-­‐5p	   and	  miR-­‐15b	   did	   not	  
show	  a	  statistically	  significant	  differential	  expression	  between	  the	  two	  groups.	  
miR-­‐320a	  was	  significantly	  less	  expressed	  in	  plasma	  samples	  of	  AC	  patients	  compared	  to	  
HC.	  
Then,	  we	  evaluated	  the	  miRNA-­‐320a	  expression	  in	  the	  AC	  patients	  and	  age-­‐matched	  HC-­‐
cohort	  (n=35	  each)	  (Figure	  16,	  panel	  A).	  miR-­‐320a	  expression	  resulted	  variably	  distributed	  
in	  HC	  (Figure	  16,	  panel	  B)	  and	  significantly	  down-­‐regulated	  in	  AC	  patients,	  with	  a	  0.39	  ±	  
0.02	  fold	  decrease;	  (p=	  0.003)	  (Figure	  16,	  panel	  A).	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Figure 16 | miR-320a expression in AC patients vs. HC. 
Panel A: miR-320a expression in 35 AC patients (red column)  vs. 35 HC (grey column), expressed as fold 
change, black stars represent p values<0.01; panel B: dispersion of ΔCt values in HC (grey squares) vs AC 
patients (red dots.).	  
21. miR-­‐320a	  accuracy	  
In	   order	   to	   evaluate	   the	   accuracy	  of	  miR-­‐320a	   to	  discriminate	  AC	  patients	   from	  HC	  we	  
performed	  Receiver	  Operating	  Characteristic	  (ROC)	  curve	  analysis	  (Figure	  17).	  	  
The	  ROC	   curve	   is	   a	   tool	   for	  diagnostic	   test	   evaluation,	  because	   it	   helps	   to	  evaluate	   the	  
accuracy	   of	   a	   test	   in	   discriminating	   the	   presence	   of	   the	   disease	   from	   the	   lack	   of	   the	  
disease	   in	   the	   examinated	   cases.	   In	   a	   ROC	   curve	   the	   true	   positive	   rate	   (Sensitivity)	   is	  
plotted	  as	  a	   function	  of	   the	   false	  positive	   rate	   (100-­‐Specificity)	   for	  different	  points	  of	   a	  
parameter.	   In	  our	  case,	  each	  point	  on	   the	  ROC	  curve	   represents	  a	   sensitivity/specificity	  
pair	  corresponding	  to	  miR-­‐320a	  ΔCt	  values	  (AC	  patients	  vs.	  HC).	  The	  area	  under	  the	  ROC	  
curve	   (AUC)	   is	   a	   measure	   of	   how	   well	   a	   parameter	   can	   distinguish	   between	   the	   two	  
diagnostic	   groups	   (AC	   vs.	   HC).	   ROC	   analysis	   showed	   an	   AUC	   value	   of	   0.77	   (p=0.03),	  
indicating	   a	   good	   accuracy	   of	   miR-­‐320a	   as	   a	   potential	   discriminating	   marker	   of	   the	  
diagnosis	  of	  AC.	  
Data	  analysis	  showed,	  for	  instance,	  that	  for	  ΔCt	  values	  of	  <-­‐5.55	  AC	  diagnosis	  has	  65%	  of	  
sensitivity	  and	  80%	  of	  specificity.	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Figure 17 | ROC curve, representing the accuracy of miR-320a in detecting AC patients. 
Sensitivity and specificity are plotted for each ΔCt value. ROC curve shows a significant AUC of 0.77 (p<0.05). 
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22. miR-­‐320a	  in	  other	  arrhythmias	  	  
In	   addition,	   to	   evaluate	  whether	   the	   lower	   expression	   of	  miR-­‐320a	   in	   AC	   patients	  was	  
specific	   of	   this	   disease,	  we	   decided	   to	   investigate	   if	   the	   same	   findings	  were	   present	   in	  
other	  arrhythmic	  disease.	  	  
Therefore	   in	   order	   to	   exclude	   that	   miR-­‐320a	   regulation	   was	   associated	   to	   unspecific	  
ventricular	   arrhythmogenic	   phenotype,	   its	   expression	   was	   tested	   in	   patients	   with	  
idiopathic	   ventricular	   tachycardias	   (IVT)	   (n=20),	   a	   disease	  which	   could	  be	   considered	   in	  
differential	   diagnosis	   with	   AC,	   and	   it	   is	   characterized	   by	   arrhythmias	   originating	   often	  
within	   the	   same	  anatomical	   site	   as	  AC	  but	  with	  different	  underlying	  pathophysiological	  
processes.	   Also	   a	   group	   of	   patients	   affected	   by	   ischemic	   ventricular	   arrhythmias	   (IC)	  
(n=24)	  was	  included	  in	  the	  study.	  
MiR-­‐320a	  was	  equally	  expressed	  in	  patients	  with	  IVT,	  IC	  and	  HC	  (	  fold	  change	  1.09±0.15,	  
p=ns;	   fold	   change	   0.74±0.22,	   p=ns)	   but	   once	   again	   was	   statistically	  more	   expressed	   in	  
patients	  with	  IVT	  compared	  to	  AC	  (	  fold	  change	  2.79±0.26,	  p<0.001)	  	  (Figure	  18).	  
	  
Figure 18 | miR-320a is downregulated only in AC. 
Fold change in miR-320a expression in all populations participating in the study: 35 HC, 35 AC, 20 IVT and 25 
IC plasma samples. Black stars represent p values respect to HC (**=p<0.01).   
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ROC	  curve	  analysis	  demonstrated	  a	  good	  accuracy	  of	  miR-­‐320-­‐a	  as	  a	  circulating	  biomarker	  
to	   distinguish	   patients	   with	   ventricular	   tachycardia	   affected	   by	   Arrhythmogenic	  
Cardiomyopathy	  and	  patients	  with	  Idiopathic	  Ventricular	  Tachycardia	  (Figure	  19).	  
 
 
Figure 19 | ROC curve analysis for accuracy of miR-320-a. 
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23. Correlations	  between	  miR-­‐320a	  and	  disease	  severity	  
We	  hypothesised	  that	  miR-­‐320a	  expression	  could	  be	  associated	  with	  clinical	  signs	  of	  AC	  
severity.	   We	   performed	   the	   evaluation	   of	   the	   occurrence	   of	   major	   arrhythmic	   events	  
(MAE)	   and	   the	   semi-­‐quantitative	   assessment	   of	   the	   functionality	   of	   the	   left	   and	   right	  
ventricle,	   measured	   with	   ejection	   fraction	   (EF)	   and	   Tricuspid	   Annular	   Plane	   Systolic	  
Excursion	  (TAPSE),	  respectively.	  Further	  investigations	  about	  the	  role	  of	  the	  currently	  use	  
drug	  therapies	  allowed	  us	  to	  conclude	  that	  the	  presence	  of	  antiarrhythmic	  therapies	  did	  
not	  influence	  miR-­‐320a	  expression.	  	  
	  As	   shown	   in	   Figure	   20	  we	   observed	   a	   significant	   correlation	   (r2=0.20	   p<0.04)	   between	  
impairment	  of	  LV	  function	  and	  ΔCt	  expression:	  patients	  with	  a	   lower	  expression	  of	  miR-­‐
320a	  showed	  a	  greater	  impairment	  in	  EF.	  
	  
Figure 20 | Linear regression of ΔCt vs. EF percentage values in AC patients. 
The regression line represents the interpolation between miR-320a ΔCt values and left-EF percentage. Dots 
represent single values per AC patient. 
Moreover,	   as	   shown	   in	  Figure	  21	  a	   similar,	   even	  not-­‐significant	   trend	   (r2=0.12;	  p=0,08),	  
was	  observed	  in	  the	  correlation	  between	  TAPSE	  impairment	  and	  miR-­‐320a	  ΔCt.	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Figure 21 | Linear regression of ΔCt vs. TAPSE values (mm) in AC patients. 
The regression line represents the interpolation between miR-320a ΔCt values and TAPSE percentage. Dots 
represent single values per AC patient. 
We	  then	  evaluate	  miR-­‐320a	  plasma	  expression	  and	  its	  possible	  correlation	  with	  areas	  of	  
scar	  (percentage	  of	  LGE)	  into	  the	  right/left	  ventricle,	  calculated	  by	  CMR	  in	  12	  AC	  patients.	  
As	  seen	  in	  Figure	  22	  we	  observed	  that	  fibro-­‐adipose	  progression	  could	  be	  linked	  with	  miR-­‐
320a	   expression	   even	   if	   the	   simple	   regression	   analysis	   did	   not	   result	   in	   a	   statistical	  
correlation	  (r2	  value	  0.26	  and	  p=0.08).	  
	  
Figure 22 | Correlation between miR-320a expression (ΔCt) and scar areas obtained at the 
CMR obtained. 
The regression line represents the interpolation between miR-320a ΔCt values and scar areas. Dots represent 
single values per AC patient. 
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In	  addition	  we	  analysed	  mir-­‐320a	  expression	  and	  the	  presence	  of	  scar	  at	  CMR	  and	  EAM	  
low-­‐voltage	  areas	  obtained	  in	  the	  RV/LV	  with	  CARTO	  system	  in	  AC	  patients.	  	  
The	  correlation	  between	  miR-­‐320a	  expression	  (ΔCt)	  and	  unipolar	  scar	  areas	  obtained	  with	  
EAM	  despite	  not	  statistically	  associated,	  showed	  a	  common	  trend	  (p=0.07).	  (Figure	  23).	  
	  
Figure 23 | Correlation between miR-320a expression (ΔCt) and scar areas obtained at the 
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24. miR-­‐320a	  characterisation	  
It	   has	   been	   demonstrated	   that	   miR-­‐320a,	   in	   prostate	   cancer,	   inhibited	   Wnt/β-­‐catenin	  
signalling	   pathway	   by	   targeting	   the	   3’-­‐UTR	   of	   β-­‐catenin	   mRNA	   134.	   Wnt	   pathway	   is	  
involved	  in	  AC	  pathogenesis	  29,	  adipogenic	  differentiation	  135	  and	  it	  is	  regulated	  in	  human	  
mesenchymal	  stromal	  cells	  136.	  In	  addition	  it	  was	  recently	  published	  that	  human	  skeletal-­‐
MSCs	  undergo	  adipogenic	  differentiation	  through	  a	  mechanism	  involving	  miR-­‐320	  family	  
137.	  According	  to	  these	  literature	  data,	  we	  speculate	  that	  the	  lower	  plasmatic	  expression	  
of	  miR-­‐320a	  we	  observed	  in	  AC	  patients	  may	  correlate	  with	  the	  adipose	  substitution	  in	  AC	  
hearts.	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25. Cardiac	  Mesenchymal	  Stromal	  Cells	  in	  AC	  	  
Since	   Cardiac	   Mesenchymal	   Stromal	   Cells	   (C-­‐MSCs)	   from	   AC	   ventricular	   samples	   have	  
been	  obtained	  in	  our	  laboratory	  and	  have	  been	  used	  as	  in	  vitro	  model	  of	  AC,	  we	  decided	  
to	  evaluate	  miR-­‐320a	  in	  this	  model.	  
C-­‐MSC	  primary	  lines	  of	  AC	  (n=6)	  and	  NON-­‐AC	  (n=5)	  were	  available	  for	  in	  vitro	  study.	  	  
To	  characterize	  the	   immunophenotype	  of	  C-­‐MSCs,	  different	  plasma	  membrane	  domains	  
(CD)	  were	  assessed	  to	  exclude	  hematopoietic	  and	  endothelial	  lineage	  origin	  and	  confirm	  
therefore	  their	  mesenchymal	  characteristics	  of	  the	  obtained	  cells.	  	  
As	   shown	   in	   Table	   5	   our	   cells	   are	   of	   mesenchymal	   origin,	   they	   show	   low	   presence	   of	  
CD31.	  The	  expression	  of	  the	  hematopoietic	  markers	  CD34	  and	  CD45	  was	  absent.	  	  
	  
Table 5 | Detailed FACS analysis of AC and NON-AC C-MSCs. 
All FACS antibodies used for the immunophenotype analysis. AC and NON-AC colum represent the mean 





	  	   66	  
	  
As	   shown	   both	   in	   Table	   5	   and	   Figure	   24	   our	   AC	   C-­‐MSCs	   are	   similar	   to	   NON-­‐AC	   cells	  
concerning	  both	  composition	  and	  morphology.	  CD90	   is	  poorly	  expressed	   in	  our	  cells,	  as	  
already	  described	  for	  mesenchymal	  cells	  of	  non-­‐bone	  marrow	  origin	   138,	  but	   it	   is	  a	   little	  
more	  expressed	   in	  AC	  cells	   than	   in	   controls,	   as	  expected	   in	   cells	  obtained	   from	  a	  more	  
fibrous	  and	  fibro-­‐adipose	  tissue	  139,	  140.	  
	  
Figure 24 | Representative image of C-MSCs in basal medium (T.MES) (bright field). 
Panel A: NON-AC patient-derived C-MSCs; panel B: AC patient-derived C-MSCs. 
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25.1 C-­‐MSCs	  during	  adipogenesis	  
In	   order	   to	   assess	   C-­‐MSCs	   involvement	   during	   adipogenesis	   we	   planned	   an	   in	   vitro	  
experiment	   in	   order	   to	   attempt	   to	   differentiate	   C-­‐MSCs	   in	   to	   fully	   differentiated	  
adipocytes	  thus	  mimicking	  what	  we	  are	  hypothesized	  to	  happen	  in	  the	  AC	  development.	  	  
We	  maintained	  the	  same	  plated	  number	  of	  C-­‐MSCs	  in	  adipogenic	  medium	  for	  3	  days.	  	  
As	  shown	  with	  the	  ORO	  staining	  in	  Figure	  25,	  panel	  A	  and	  B	  AC	  patients-­‐derived	  C-­‐MSCs	  
(n=6)	   accumulate	   more	   lipid	   droplets	   than	   NON-­‐AC	   patients-­‐derived	   C-­‐MSCs	   (n=5).	   In	  
addition	   the	   quantification	   of	   lipid	   staining	  measured	   through	   the	   red	   (255)	   luminance	  
with	   ImageJ	  software	  showed	  a	  statistically	   significant	   increase	  ORO	  staining	   in	  AC	  cells	  
compared	  to	  NON-­‐AC	  (p=0.004).	  
	  
	  
Figure 25 | Representative image of C-MSCs in adipogenic medium (T.ADIPO) after ORO 
staining (bright field). 
Panel A: NON-AC patient-derived C-MSCs; panel B: AC patient-derived C-MSCs; panel C:quantification of 
ORO staining in NON-AC patient-derived C-MSCs (grey column) vs AC patient-derived C-MSCs (red column). 
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25.2 miR-­‐320a	  during	  adipogenesis	  in	  C-­‐MSCs	  
We	  planned	  an	   in	  vitro	   experiment	   to	   simulate	  AC	  development	  and	  monitor	  miR-­‐320a	  
expression	  in	  the	  following	  two	  conditions:	  	  
1)	   Basal	   condition,	   in	   which	   cells	   were	   maintained	   in	   basal	   medium	   (T.MES)	   for	   72	  
hours;	  	  
2)	   Adipogenic	   condition,	   in	   which	   cells	   were	   maintained	   in	   adipogenic	   medium	  
(T.ADIPO)	  for	  21	  days.	  
As	   shown	   in	   Figure	   26,	   panel	   A	   AC	   C-­‐MSCs	   showed	   a	   lower	   miR-­‐320a	   expression,	   of	  
0.44±0.08	   fold,	   compared	   to	   NON-­‐AC,	   even	   if	   not	   reaching	   the	   statistical	   significance.	  
Instead,	   after	   21	   days	   of	   adipogenic	   induction,	   we	   observed	   that	   miR-­‐320a	   is	   present	  
homogeneously	  in	  the	  two	  populations,	  as	  seen	  in	  Figure	  26,	  panel	  B	  (1.0	  ±	  0.11	  in	  NON-­‐
AMC	  and	  0.97	  ±	  0.06	  in	  AC).	  Panel	  A	  and	  B	  show	  the	  expression	  of	  miR-­‐320a	  in	  AC	  cells	  
relative	  to	  the	  NON-­‐AC	  controls,	  normalized	  to	  1	  to	  better	  show	  the	  difference	  between	  
AC	  and	  NON-­‐AC	   samples.	   In	   Figure	  26,	   panel	   C	   the	   same	   raw	  data,	   not	  normalized	   are	  
plotted	  as	  ΔCt,	  representing	  the	  miR-­‐320a	  expression	  values,	  in	  the	  two	  conditions:	  miR-­‐
320a	  expression	  in	  C-­‐MSCs	  at	  basal	  level	  and	  after	  21	  days	  of	  adipogenic	  treatment.	  Here	  
we	   evaluated	   the	   change	   in	   miR-­‐320a	   levels	   during	   adipogenesis	   for	   each	   group.	   We	  
observed	  that	  both	  groups	  showed	  an	  increase	  in	  the	  miRNA	  levels	  during	  adipogenesis,	  
even	  if	  more	  consistent	  in	  AC	  C-­‐MSCs.	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Figure 26 | miR-320a expression during adipogenesis. 
Panel A: fold change in miR-320a expression in 5 NON-AC C-MSCs (grey column) vs. 6 AC C-MSCs (red 
column) at basal condition (T.MES). Panel B: fold change in miR-320a expression in 5 NON-AC C-MSCs 
(grey column) vs. 6 AC C-MSCs (red column) after adipogenic differentiation (T.ADIPO). Panel C: miR-320a 
ΔCt (miR-320a Ct – miR-210 Ct values) variation in 5 NON-AC C-MSCs (grey line) vs. 6 AC C-MSCs (red 
line) at basal condition (T.MES) and after 21d adipogenic differentiation (T.ADIPO). The graph represents the 
reverse ΔCt values for the two conditions, since lower ΔCt values correspond to higher miR-320a expression.
All the experiments were performed in duplicate.	  	    
	  DISCUSSION	  
	  
Arrhythmogenic	   Cardiomyopathy	   (AC)	   is	   a	   rare	   pathology,	   which	   affects	   mainly	  
young	   and	   athletes,	   leading	   to	   ventricular	   tachyarrhythmia,	   right	   and/or	   biventricular	  
impairment	  and	  in	  the	  worst	  case	  to	  Sudden	  Cardiac	  Death	  (SCD).	  
Clinical	   diagnosis	   remains	   challenging	   because	   of	   its	   great	   variability	   in	   phenotypic	  
manifestations,	   incomplete	   penetrance,	   and	   age-­‐related	   progression.	   Mainly	   at	   its	  
exordium,	  AC	   is	   characterized	  by	  a	  “concealed	  phase”,	   in	  which	  ventricular	  arrhythmias	  
and	  SCD	  are	  not	  infrequent,	  even	  without	  overt	  manifestation	  of	  the	  disease.	  
Diagnosis	  is	  based	  on	  a	  scoring	  algorithm	  based	  on	  electrophysiological,	  morphologic	  and	  
genetic	  parameters	  that	  often	  does	  not	  allow	  to	  reach	  a	  clear	  diagnosis	  leaving	  high-­‐risk	  
patients	  to	  cope	  with	  an	  unsolved	  issue.	  	  
Data	  obtained	  during	   the	  past	  year	   represents	  a	  proof	  of	   concept	  aiming	   to	   identify	  an	  
early	   and	   non-­‐invasive	   biomarker	   for	   the	   diagnosis	   of	   AC	   and	   the	   preliminary	   data	  
obtained	   from	  cellular	  model	  may	   represents	  basis	   for	   future	  mechanistic	   studies	   in	  AC	  
pathogenesis.	  	  
Thus,	   a	   successful	   early	   diagnosis,	   prevention	   of	   the	   deadly	   complications	   and	   the	  
therapeutic	  approach	  for	  this	  disease	  depends	  heavily	  on	  the	  clinical	  biomarkers	  for	  early	  
detection	  of	  the	  presence	  and	  progression	  of	  the	  disease,	  as	  well	  as	  the	  prediction	  after	  
the	   clinical	   intervention.	   However,	   the	   current	   clinical	   biomarkers	   do	   not	   allow	   to	  
specifically	   distinguish	   between	   those	   patients	   who	   will	   develop	   the	   more	   aggressive	  
form	   of	   the	   disease	   and	   those	   who	   should	   avoid	   overtreatment	   for	   less	   severe	   forms	  
enabling	  physicians	  to	  tailor	  treatment	  for	  individual	  patients.	  Recently,	  some	  researchers	  
have	  demonstrated	  that	  plasma	  miRNAs	  are	  sensitive	  and	  specific	  biomarkers	  of	  various	  
diseases.	  The	  primary	  aim	  of	  the	  study	  was	  to	  investigate	  whether	  miRNAs	  present	  in	  the	  
plasma	  of	  AC	  patients	  can	  be	  used	  as	  diagnostic	  and	  prognostic	  biomarkers.	  
After	  an	  initial	  screening	  of	  367miRNAs	  we	  identified	  135	  miRNAs	  differentially	  expressed	  
in	  the	  two	  cohorts	  (AC	  and	  HC). In	  miRNA	  microarray	  data	  analysis,	  the	  main	   interest	   is	  
usually	  focused	  on	  whether	  a	  specific	  miRNA	  or	  a	  set	  of	  miRNAs	  is	  differentially	  expressed	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in	  the	  different	  sample	  populations.	  In	  order	  to	  identify	  which	  of	  the	  135	  miRNA	  could	  be	  
involved	  in	  AC,	  we	  initially	  set	  the	  following	  cut-­‐off:	  the	  miRNA	  should	  have	  at	  least	  a	  two-­‐
fold	  change	   in	  expression	  and	  has	   to	  have	  a	  statistically	  different	  expression	   in	   the	   two	  
groups	  of	  patients.	  Since	  we	  initially	  performed	  this	  test	  only	  in	  six	  patients,	  to	  avoid	  any	  
bias	   related	   to	   the	   small	   sample,	  we	   included	   in	   the	  validation	  process	  miRNAs	   that,	  at	  
the	  Volcano	  plot,	  localized	  close	  to	  the	  set	  threshold.	  	  
Because	   the	   amount	   of	   miRNA	   in	   plasma	   samples	   is	   too	   low	   to	   be	   quantified	   by	  
traditional	  methods,	  all	   results	  need	   to	  be	  compared	   to	  an	   internal	   standard.	   From	  the	  
data	  obtained	  from	  the	  Taqman	  card	  array	  we	  were	  also	  able	  to	   identify	  which	  miRNAs	  
were	   potentially	   equally	   expressed	   in	   the	   two	   cohorts.	   Testing	   these	  miRNAs	   by	   single	  
miRNA	  qRT-­‐PCR	  we	  were	   able	   to	   identify	   and	   validate	   them	  as	   normalizers.	   Among	   15	  
miRNAs	  equally	   expressed	   in	   the	   two	  groups	  of	  patients,	  miR-­‐210	  was	   chosen	  given	   its	  
high	  expression	  and	  its	  homogeneous	  Ct	  distribution	  in	  both	  groups.	  Normalization	  is	  an	  
essential	   step	   in	   microarray	   gene-­‐expression	   data	   analysis.	   It	   helps	   to	   reduce	   non-­‐
biological	   errors	   and	   to	   convert	   raw	   data	   to	   valid	   results.	   In	   particular	   the	   choice	   of	  
normalizers	   is	   an	   important	   debated	   issue	   in	   the	   field	   of	   plasma	   screening:	   one	   of	   the	  
challenges	  of	  plasmatic	  miRNAs	  profiling	  is	  the	  discovery	  of	  an	  established	  housekeeping	  
genes	   for	   data	   normalization.	   Another	   common	   approach	   to	   this	   purpose	   is	   to	   add	  
exogenous	   synthetic	  miRNA	  mimics	   (e.g.	   synthetic	  C.	   elegans	  miRNAs	   that	  do	  not	  have	  
homologous	   sequences	   in	   humans),	   in	   plasma	   samples,	   before	   RNA	   extraction	   as	  
normalizer.	   Anyway,	   despite	   the	   use	   of	   a	   fixed	   plasma	   volume,	   this	   method	   does	   not	  
consider	  that	  RNA	  amount	  may	  be	  variable	  in	  different	  samples.	  Further,	  it	  is	  well	  known	  
in	  literature	  that	  exogenous	  miRNAs	  are	  not	  so	  stable	  as	  endogenous	  ones	  and	  they	  may	  
be	   degraded,	   modifying	   expected	   results.	   Therefore,	   adding	   a	   fixed	   amount	   of	   one	   or	  
several	   synthetic	   miRNAs	   into	   samples	   containing	   variable	   amounts	   of	   RNA	   for	  
normalizing	  with	  qRT-­‐PCR	  is	  not	  the	  best	  choice.	  
Among	  the	  8	  miRNAs	  initially	  identified	  because	  they	  were	  differently	  expressed	  between	  
AC	  and	  HC,	  only	  miR-­‐320a	  overcame	  the	  validation	  process,	  performed	  via	  single	  miRNA	  
qRT-­‐PCR	  in	  plasma	  of	  additional	  6	  AC	  compared	  with	  6	  age-­‐matched	  HC.	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In	  order	  to	  further	  validate	  the	  role	  miR-­‐320a	  as	  a	  putative	  biomarker	  of	  this	  rare	  disease	  
it	   was	   assayed	   in	   plasma	   samples	   coming	   from	   a	   remarkable	   large	   population	   of	   AC	  
patients	  (n=35).	  	  Validation	  data	  were	  confirmed	  as	  seen	  in	  Figure	  16,	  panel	  A	  	  
In	  our	  selected	  cohort	  of	  AC	  patients,	  compared	  to	  HC,	  miR-­‐320a	  showed	  a	  61%	  reduction	  
of	   its	   expression	   that	   we	   found	   to	   be	   statistically	   significant,	   indicating	   a	   strong	  
correlation	  between	  miR-­‐320a	  and	  AC	  occurrence.	  	  
A	  significant	  reduction	  (61%)	  in	  miR-­‐320a	  expression	  was	  found	  in	  our	  selected	  cohort	  of	  
AC	   patients	   when	   compared	   to	   HC,	   suggesting	   a	   strong	   correlation	   between	  miR-­‐320a	  
expression	  and	  the	  occurrence	  of	  AC.	  Despite	   these	   important	   findings,	  we	  were	  aware	  
that	   a	   comparison	   with	   a	   population	   of	   HC	   could	   have	   been	   considered	   an	   intrinsic	  
limitation	  of	  the	  study	  with	  a	  weakening	  effect	  on	  the	  relative	  conclusions.	  In	  fact	  in	  the	  
everyday	   clinical	   setting,	   when	   we	   suspect	   AC	   could	   affect	   a	   patient,	   the	   differential	  
diagnosis	   should	   be	  made	  with	   other	   conditions	   leading	   to	   ventricular	   arrhythmias	   like	  
IVT.	  In	  order	  to	  avoid	  this	  selection	  bias	  concerning	  the	  reference	  population	  we	  decided	  
to	  recruit	  NON-­‐AC	  and	  NON-­‐HC	  patients	  and	  in	  particular	  we	  obtained	  plasma	  samples	  of	  
patients	   affected	   by	   idiopathic	   ventricular	   tachycardia	   (VT).	   By	   testing	   miR-­‐320a	  
expression	   in	   this	  population	  we	  aimed	  to	   further	  confirm	   its	   specificity	   in	  diagnosis	  AC	  
and	  therefore	  its	  possible	  clinical	  utility.	  IVT	  and	  HC	  patients	  had	  a	  very	  similar	  miR-­‐320a	  
plasma	   levels,	   further	   enforcing	   the	   hypothesis	   that	   miR-­‐320a	   could	   play	   a	   role	   in	   AC	  
development.	  
After	   having	   identified	   miR-­‐320a	   as	   a	   diagnostic	   tool	   for	   AC	   diagnosis,	   we	   tried	   to	  
investigate	   its	   role	   as	   a	   tool	   for	   risk	   stratification.	   First	   of	   all	   we	   did	   not	   find	   any	  
correlation	  between	  the	  level	  of	  miR-­‐320a	  expression	  and	  any	  anti-­‐arrhythmic	  drug	  taken	  
from	  the	  patients,	  thus	  excluding	  them	  as	  confounding	  variables.	  	  
Unfortunately	  we	  did	  not	   find	   any	   significant	   correlation	  between	  miR-­‐320a	  expression	  
and	   right	   ventricular	   function	  measured	   by	   TAPSE,	   but	   a	   slightly	   significant	   correlation	  
with	  left	  ventricular	  EF.	  Unexpectedly,	  lower	  EF	  (meaning	  a	  greater	  left	  ventricle	  damage)	  
was	  associated	  with	  higher	  miR-­‐320a	  expression,	  similar	  to	  what	  was	  found	  in	  HC.	  On	  the	  
contrary	  of	  what	  we	  have	  found	  we	  were	  expecting	  an	  inverse	  correlation:	  the	  lower	  miR-­‐
320a	   levels	  were	   the	  worse	   the	  patient’s	  phenotype	  should	  be.	  Anyway,	  more	  data	  are	  
needed	  to	  confirm	  these	  results	  and	  to	  explain	  them.	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miR-­‐320a	   expression	   and	   AC	   severity	   was	   further	   evaluated	   by	   EAM.	   As	   previously	  
described	  RV	  EAM	  is	  representative	  of	  fibro-­‐adipose	  substitution	  in	  AC	  patients.	  64,	  65	  
We	  observed	  that	  miR-­‐320a	  slightly	  correlate	  with	  low-­‐potential	  scar	  areas,	   in	  particular	  
in	   the	   unipolar	   voltage	   mapping.	   Indeed,	   patients	   with	   higher	   miR-­‐320a	   expression	  
showed	   small	   low-­‐potential	   scar	   areas;	   on	   the	   contrary,	   patients	   with	   lower	  miR-­‐320a	  
expression	  showed	  greater	  low-­‐potential	  scar	  areas.	  It	  is	  intriguing	  that	  a	  miRNA	  involved	  
in	   adipogenic	   differentiation	   seems	   to	   go	   along	   with	   the	   adipose	   scar	   in	   AC	   patients’	  
hearts.	  Enlarging	  our	  cohort,	  we	  may	  be	  able	  to	  offer	  a	  new	  tool	  to	  evaluate	  adipogenic	  
progression	  in	  patients’	  hearts.	  
Plasma	  biomarkers	  are	  actively	   investigated	  because	  of	  their	  non-­‐invasiveness:	  recently,	  
BIN1	   has	   been	   proposed	   as	   a	   new	   circulating	   biomarker	   that	   correlates	   with	   HF	   and	  
predicts	  arrhythmias	   in	  AC	  patients	   63.	  Despite	   its	  high	  accuracy	   in	  detecting	  arrhythmic	  
events	  and	  in	  identifying	  the	  worst	  AC	  phenotype,	  it	  has	  only	  been	  evaluated	  in	  AC	  group	  
and	   not	   in	   patients	   affected	   by	   other	   pathologies;	   therefore	   it	   cannot	   be	   considered	  
specific	  for	  AC.	  Since	  BIN1	  recognized	  HF,	   it	  might	  only	  correlate	  with	  cardiac	  functional	  
status,	   independently	   from	   AC.	   A	   cohort	   of	   NON-­‐AC	   HF	   patients	   would	   be	   needed	   to	  
confirm	   BIN1	   as	   an	   AC-­‐specific	   biomarker.	   It	   would	   be	   interesting	   to	   evaluate	   possible	  
correlation	  between	  miR-­‐320a	  and	  BIN1	  or	   to	  combine	  the	  two	  circulating	  molecules	   in	  
order	  to	  get	  an	  AC-­‐specific	  patients	  risk	  stratification.	  
Beside	   our	   AC	   patients’	   male	   cohort	   we	   had	   the	   chance	   to	   consider	   only	   5	   women	  
clinically	   affected	   by	   AC,	   according	   with	   the	   higher	   male	   prevalence	   between	   patients	  
hospitalized	   at	   CCM,	   than	   described	   in	   literature18:	   indeed	  we	   observed	   a	  male:female	  
ratio	  of	  6.6:1.	  We	  evaluated	  miR-­‐320a	  expression	  in	  their	  plasma	  samples	  coming	  from	  5	  
women	   affected	   by	  AC	   and	   in	   4	   age-­‐matched	   female	  HC.	   AC	  women	   showed	   a	   slightly	  
augmented	   miR-­‐320a	   expression	   compared	   to	   HC.	   Noteworthy,	   this	   result	   showed	   an	  
opposite	   trend	   compared	   to	  what	   observed	   in	  male	   patients.	   Anyway,	   this	   preliminary	  
data,	  far	  to	  be	  conclusive,	  has	  to	  be	  considered	  strongly	  promising	  supporting	  the	  choice	  
to	  enlarge	  the	  sample	  size.	  Intriguingly,	  software	  like	  TargetScan	  revealed	  that	  miR-­‐320a	  
might	   bind	   the	   estrogen-­‐related	   receptor	   gamma,	   constituting	   an	   idea	   for	   future	  
mechanistic	   studies	   to	   explain	   higher	   male	   prevalence.	   Future	   studies	   are	   needed	   to	  
prove	  this	  hypothesis.	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The	  link	  between	  AC	  and	  physical	  exercise	  is	  still	  unclear.	  For	  many	  AC	  patients	  exercise	  
may	   be	   the	   cause	   of	   arrhythmias	   141.	   Several	   reports	   also	   show	   the	   occurrence	   of	   SCD	  
during	  physical	  exertion	  142.	  Recently	   literature	  even	  focused	  on	  a	  new	  phenology	  of	  AC	  
named	  exercise-­‐induced	  AC	  143,	   144.	  Most	  of	  the	  recruited	  patients	  (28/33)	  were	  athletes	  
or	  former-­‐athletes,	  suggesting	  a	  possible	  role	  of	  training	  in	  predisposing	  to	  a	  worst	  clinical	  
manifestation.	   It	   would	   be	   very	   interesting	   to	   evaluate,	   in	   the	   future,	   miR-­‐320a	  
expression	  in	  a	  cohort	  of	  endurance	  or	  resistance	  athletes	  assessing	  the	  independency	  of	  
our	   findings	   from	   strong	   physical	   activity.	   Additionally,	   it	   would	   be	   very	   helpful	   to	  
compare	   2D-­‐echo	   data	   of	   this	   cohort	   in	   order	   to	   assess	   any	   possible	   correlation	   with	  
ventricular	  functionality	  and	  exercise-­‐induced	  remodeling	  of	  the	  heart.	  
Our	   AC	   cohort,	   as	   described	   in	   literature,	   showed	   a	   great	   genotypic	   heterogeneity.	  
Genetic	  analysis	  revealed	  private	  mutations	   in	  different	  desmosomal	  genes	  (e.g.	  PKP2	  is	  
the	   most	   common	   mutated	   gene).	   The	   evaluation	   of	   possible	   correlations	   between	  
patients	   carrying	   mutations	   in	   the	   same	   gene	   and	   miR-­‐320a	   expression	   could	   be	   very	  
interesting	   to	   study.	   It	   may	   lead	   to	   further	   understand	   miR-­‐320a	   involvement	   in	   AC	  
development.	  Moreover,	  a	  highly	  variable	  penetrance	  was	  found	  in	  several	  families	  with	  
an	  AC	  family	  history.	  Despite	  the	  inheritance	  of	  the	  same	  mutation	  AC	  manifestations	  are	  
variable	   and	   does	   not	   depend	   only	   on	   the	   genetic	   deficiencies;	   it	   would	   be	   very	  
interesting	  to	  evaluate	  miR-­‐320a	  plasmatic	  levels	  in	  our	  “AC	  families”,	  comparing	  affected	  
individuals	  to	  non-­‐affected	  relatives,	  carrying	  the	  same	  genetic	  mutation.	  	  
The	  most	  intriguing	  hypothesis	  coming	  from	  our	  data	  was	  the	  putative	  effect	  of	  miR-­‐320a	  
in	   the	   heart	   tissue	   derangement	   in	   AC	   and	   in	   particular	   the	   replacement	   of	   the	   heart	  	  
tissue	  with	   fat.	   Recent	   studies	   have	   demonstrated	   that	  microRNAs	   are	   also	   involved	   in	  
adipocyte	   differentiation.	   In	   vivo	   and	   in	   vitro	   studies	   have	   revealed	   that	   various	  
microRNAs	  affect	  adipogenesis	  by	   targeting	  several	  adipogenic	   transcription	   factors	  and	  
key	  signaling	  molecules.	  
miR-­‐320a	  in	  particular	  was	  recently	  reported	  to	  be	  involvement	  in	  adipogenesis	  145	  so	  we	  
looked	  	  at	  miR-­‐320a	  expression	  in	  a	  cellular	  model	  of	  AC	  adipogenesis.	  C-­‐MSCs,	  primary	  
cells,	   directly	   obtained	   from	   AC	   ventricular	   bioptic	   samples,	   recapitulate	   in	   vitro	   AC	  
pathogenesis	  (including	  Wnt	  pathway	  mis-­‐regulation)	  besides	  contributing	  to	  adipocytes	  
development	   in	   vivo	   133.	  We	  observed	   that	  C-­‐MSCs	  might	  play	  a	   crucial	   role	  during	  AC-­‐
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correlated	   adipose	   substitution	   in	   human	   hearts.	   Indeed,	   we	   observed	   that	   C-­‐MSCs	  
isolated	   from	   human	   AC	   hearts	   are	   in	   vitro	   more	   prone	   than	   C-­‐MSCs	   obtained	   from	  
control	   hearts	   not	   only	   to	   accumulate	   fat	   (lipogenesis),	   but	   to	   specifically	   differentiate	  
into	  adipocytes.	  These	  data	  are	  very	  important	  to	  define	  AC	  pathogenesis	  and	  their	  role	  
should	  be	  more	  investigated	  to	  prevent	  the	  adipogenic	  substitution	  in	  AC	  patients’	  hearts.	  
Besides	  C-­‐MSCs	  role	  in	  AC	  we	  decided	  to	  evaluate	  miR-­‐320a	  role	  during	  adipogenesis	  in	  C-­‐
MSCs.	   In	   basal	   conditions	   (T.MES),	   unexpectedly,	   AC	   C-­‐MSCs	   showed	   a	   trend	   of	   lower	  
miR-­‐320a	   expression	   compared	   to	   NON-­‐AC	   (Figure	   26,	   panel	   A),	   as	   seen	   in	   plasma	  
samples.	   Despite	   the	   strong	   consistency	   of	   results	   in	   plasma	   and	   cell	   model,	   we	   were	  
expecting	   miR-­‐320a	   expression	   of	   AC	   C-­‐MSCs	   in	   basal	   medium	   higher	   than	   NON-­‐AC,	  
because	  of	  the	  predisposition	  of	  AC	  cells	  to	  adipogenesis.	  To	  explain	  these	  data	  we	  could	  
speculate	  that	  a	  sort	  of	  protective	  mechanism	   is	  carried	  out	  by	  AC	  cells	   to	  control	   their	  
genetic	  predisposition	  to	  fat	  accumulation	  by	  keeping	  miR-­‐320a	  at	  low	  levels.	  This	  will	  be	  
the	   subject	   of	   further	   in-­‐depth-­‐analysis.	   Nevertheless,	   during	   adipogenesis,	   miR-­‐320a	  
levels	   increased	   both	   in	   AC	   and	   NON-­‐AC	   in	   C-­‐MSCs	   (Figure	   26,	   panel	   B),	   confirming	  
literature	   data	   _ENREF_134.	   In	   this	   condition	   the	   difference	   between	   AC	   and	   NON-­‐AC	  
miRNA	   expression	   levelled	   (Figure	   26,	   panel	   C),	   since	   miR-­‐320a	   expression	   increased	  
more	  in	  AC	  cells,	  as	  expected.	  This	  result	   is	   in	  agreement	  with	  the	  mis-­‐regulation	  of	  the	  
Wnt/β-­‐catenin	   pathway	   in	   AC	   cells	   and	   with	   the	   interference	   of	   miRNAs	   in	   β-­‐catenin	  
expression.	   It	  will	   be	   very	   interesting	   to	  evaluate	  miR-­‐320a	  expression	   in	   supernatants-­‐
derived	  RNA	  in	  order	  to	  elucidate	  putative	  release	  mechanisms	  that	  can	  recapitulate	  what	  
we	  observed	  in	  plasma	  AC	  samples.	  	  
Despite	   our	   present	   results,	   our	   understanding	   of	   how	   miRNAs	   function	   in	   AC	  
developmental	   and	   disease	   pathways	   is	   really	   far	   to	   be	   elucidated	   and	   numerous	  
conceptual	  and	  experimental	  questions	  still	   remain	  unsolved.	  To	  date,	  only	  a	  handful	  of	  
the	   hundreds	   of	   miRNAs	   expressed	   in	   cardiovascular	   system	   have	   been	   functionally	  
analyzed.	   The	   ability	   of	   these	  miRNAs	   to	   fine-­‐tune	   gene	   expression	   programs	   portends	  
their	   importance	   in	   many	   facets	   of	   cardiac	   biology.	   It’s	   a	   virtual	   certainty	   that	   many	  
unexplored	   roles	   of	   miRNAs	   in	   control	   of	   normal	   and	   abnormal	   cardiac	   function	   are	  
awaiting	  discovery.	  Our	  present	  findings	  are	  clearly	  an	  advances	  in	  understanding	  the	  role	  
of	  miRNAs	  in	  pathological	  AC.	  	  	  In	  summary,	  to	  date	  studies	  have	  identified	  MiR-­‐320a	  as	  a	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candidate	   miRNAs	   which	   can	   accelerate	   adipocyte	   differentiation.	   These	   miRNAs	   may	  
provide	  promising	  candidates	  to	  design	  specific	  drugs	  able	  to	  counteract	  the	  heart	  muscle	  
to	   adipose	   tissue	   differentiation.	   However,	   it	   remains	   important	   to	   examine	   whether	  
miRNAs	  and	  in	  particular	  MiR-­‐320a	  which	  regulates	  adipocyte	  differentiation	   in-­‐vitro	  are	  
dysregulated	  in	  human	  AC	  in-­‐vivo.	  	  	  
	  CONCLUSIONS	  
	  
This	   is	   the	   first	   study	   identifying	  miR-­‐320a	   as	   a	   possible	   new	   biomarker	   for	   the	  
diagnosis	   of	   AC.	   In	   our	   cohort	   of	   patients	   the	   level	   of	   expression	   of	   miR-­‐320a	   was	  
constantly	   lower	   in	   patients	   with	   a	   diagnosis	   of	   AC	   than	   in	   controls	   and	   patients	   with	  
ventricular	   arrhythmias	   with	   a	   different	   pathogenesis	   (IVT	   and	   IC).	   In	   particular,	   the	  
expression	  of	  miR-­‐320a	  has	  a	  fairly	  good	  accuracy	  in	  discriminating	  AC	  vs.	  IVT	  patients.	  
Unfortunately	  we	  did	  not	  find	  in	  the	  present	  research	  a	  clear	  statistical	  correlation	  
between	  the	  level	  of	  expression	  of	  miR-­‐320a	  and	  the	  severity	  of	  AC,	  but	  we	  believe	  the	  
low	  number	  of	  examinated	  patients	  could	  be	  a	  bias	   for	   these	  results.	  Moreover	  we	  can	  
speculate	  that	  miR-­‐320a	  could	  be	  just	  a	  trigger	  or	  a	  co-­‐factor	  of	  a	  more	  complex	  series	  of	  
events	  leading	  to	  the	  development	  of	  the	  disease.	  	  
We	  showed	  how	  miR-­‐320a	  is	  regulated	  during	  the	  adipogenic	  differentiation	  of	  C-­‐
CMSs	  which	  have	  been	  considered	  as	  a	  cardiac	  cellular	  model	  of	  AC,	  and	  this	  new	  findings	  
for	  sure	  will	  pave	  the	  way	  to	  future	  mechanistic	  studies	  on	  the	  epigenetic	  control	  of	  AC	  
structural	  and	  functional	  damages	  and	  in	  particular	  the	  fibro-­‐fatty	  alteration.	  
The	   novelty	   of	   the	   present	   result	   and	   in	   particular	   our	   findings	   about	   the	  
correlation	   with	   the	   expression	   of	   the	  miR-­‐320a	   and	   the	   some	   of	   the	  most	   important	  
feature	  of	  AC	  disease	  are	  of	  great	  importance	  and	  could	  justify	  future	  clinical	  trials	  aiming	  
to	  unravel	  the	  unclear	  path	  of	  AC	  diagnosis.	  
This	   study	   is	   a	   clear	   example	   of	   a	   bench	   to	   bedside	   research	   approach,	   but	   the	  
process	  of	   translating	   laboratory	  discovery	   into	  patient	  care	   is	  more	  complex	  and	  more	  
varied	  than	  it	  might	  first	  appear.	  	  
This	  research	  work	   is	  also	  an	  example	  of	  how	  to	  approach	  translational	  research	  
from	   various	   angles	   and	   coming	   up	   with	   innovative	   ways	   to	   overcome	   the	   many	  
challenges	   of	   a	   very	   complex	   disease,	   which	   is	   Arrhythmogenic	   Cardiomyopathy.	   	   The	  
close	   network	   collaboration	   between	   expert	   electrophysiologist,	   the	   molecular	   biology	  
lab	  of	  the	  Monzino	  Cardiologic	  Center	  in	  Milan	  with	  the	  researchers	  of	  the	  Cardiovascular	  
Pathology	   of	   Padova	   University,	   who	   starting	   from	   a	   clinical	   need,	   are	   attempting	   to	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sinergically	   find	   a	   solution	   potentially	   useful	   for	   the	   clinical	   management	   of	   these	   so	  
severe	  disease.	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